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CHAPTER 1
INTRODUCTION

1.1 Cardiovascular Disease
Despite significant progress in medical therapeutics, cardiovascular disease
(CVD) remains the leading cause of mortality in the United States and other
industrialized

nations [1]. Currently, CVD is responsible for more than 2200

American deaths/day, an average of one death every 39s [2] and it is predicted that
one in two healthy men and one in three healthy women will develop some form of
CVD during their lifetime [3].
Cardiovascular disease is described as a health state that affects the
cardiovascular system, and includes cardiac disease, vascular disease of the brain
and kidney, and peripheral arterial disease. Coronary heart disease (CHD) is the
most common form of heart disease. It occurs when the arteries supplying blood to
the heart become narrower due to the buildup of plaque, also known as
atherosclerosis. The site where the plaque is located determines the type of CHD,
such as coronary artery disease (plaque in the arteries supplying blood to the heart),
peripheral artery disease (plaque in the arteries supplying blood to the arms and
legs), and carotid artery disease (plaque in the arteries that supply blood to the
brain). More serious consequences of plaque formation are myocardial infarction
and stroke, which can occur when blood flow to the heart, or brain, respectively, is
severely reduced or discontinued due to the hardening and narrowing of the arteries.
Other conditions such as arrhythmia, cardiomyopathy, congenital heart defects,
and hypertensive heart disease are also considered part of CVD, but they are not

2
caused by plaque formation, which is mainly associated with an imbalanced dietary
regimen.
The prevalence of CVD is expected to increase in the next decade, mainly due to
increase in sedentary lifestyle, obesity, and aging of the population, which will
increase the incidence of atherosclerosis, stroke, acute myocardial infarction, and
other CVD related diseases. In 2008, the approximate total cost of CVD treatments
was nearly US$ 500 billion, placing CVD as a top expensive disease to both human
lives and finances [1]. Moreover, it is predicted by the American Heart Association
that by 2030, 40.5 % of the US population will be diagnosed with some form of CVD
and the total direct medical costs of CVD are projected to triple, from $273
billion/year to $818 billion, while the indirect costs will increase by 61% [4].Therefore,
it is imperative that effective measures need to be applied in prevention, early
detection, and management of CVD, as this is a very costly disease in terms of both
lives and economics.
1.2 Lipoprotein Metabolism
Cholesterol molecule was first isolated from gallstones in 1789, and since then, it
became one of the most extensive topic for research [5]. Found in all cells of the
body, cholesterol is a waxy steroid metabolite that is responsible for the structure,
permeability and fluidity of the cell membrane of higher eukaryotic systems. In
addition, cholesterol serves as a precursor for the biosynthesis of vitamin D, bile
acids, and steroid hormones [6]. Cholesterol, itself, is scattered amongst cellular
membranes, accounting for 20-25% of the lipid molecules found in the plasma [5].
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Lipids in general, including cholesterol, are not soluble in blood; therefore they
are associated to proteins for transport in an aqueous media, becoming complex
aggregates known as lipoproteins. Cholesterol, TG, and phospholipids are the major
lipids that are used for hormone synthesis, formation of the cell membrane, and
production of bile acid. Within the circulation, these aggregates are in a state of
constant flux, changing in composition and physical structure as the peripheral
tissue takes up the various components before the remnants return to the liver.
The

most

abundant

lipid

constituents

are

TG,

phospholipids

(mostly

phosphatidylcholine and sphingomyelin), cholesterol esters, free cholesterol, and
proteins known as apolipoproteins (Apo). The different protein components found in
lipids determine the overall structure and metabolism, and the interactions with the
receptor molecules in liver and peripheral tissues. However, the nomenclature is
based on the relative densities of the aggregates following ultracentrifugation, taking
into account the diameter of the broadly spherical particles. Hence, the main groups
are classified as chylomicron, very low density lipoprotein (VLDL), low density
lipoprotein (LDL), and high density lipoprotein (HDL) (Figure 1.1) [1, 7]. Furthermore,
based on advanced separation procedures, intermediate density lipoprotein (IDL)
and subclasses of HDL (HDL1, HDL2, HDL3, etc.) are often defined.
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Figure 1.1 Metabolic Pathways of Endogenous and Exogenous Lipoproteins.
Abbreviations:

Apolipoprotein

A,

A;

Apolipoprotein

B,

B-48,

B-100;

Apolipoprotein C, C; Apolipoprotein E, E; Hepatic triglyceride lipase, HTGL; High
density

lipoprotein,

HDL;

Lipoprotein

lipase,

LPL;

Lecithin-cholesterol

acyltransferase, LCAT; Low density lipoprotein, LDL; Very low density
lipoprotein, VLDL [7]
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A. Chylomicrons are the largest particles amongst all lipoproteins. Dietary
cholesterol and TG are transported to different parts of the body from the intestine
by chylomicrons, which are mediated by the enzyme lipoprotein lipase (LPL).
Chylomicrons remain present in the plasma for three to six hours after consuming a
meal, after which they are recycled. The remnant chylomicrons, containing the
dietary cholesterol, Apo E and B 48 are cleared from the circulation by the liver via a
receptor- mediated process.
B. VLDL molecule is secreted into circulation by the liver and contains mostly TG
of the remnant chylomicrons, cholesterol, cholesterol esters and specific
apolipoproteins (B100, C, and E). As the transport of VLDL molecules is
progressing, the core of TG is reduced and phospholipids on the surface are
transferred to HDL. Skeletal, cardiac, or adipose tissue receive TG from VLDL and
use it for energy, or in the case of adipose tissue, for storage. Further, a large
portion of the VLDL remnants are converted to LDL with additional loss of TG. Apo
B100 and E are the remaining proteins required for recognition of the VLDL
remnants, and LDL by the LDL receptors in the liver.
C. LDL molecules are the major carriers of cholesterol from the liver to the
peripheral tissues, where the receptors recognizing Apo B100 capture the particles.
Within these tissues, the cholesterol esters are hydrolyzed to release free
cholesterol, which is further integrated into the plasma membrane and utilized as
desired. It is widely known that high levels of LDL cholesterol increase CVD risk due
to the atherosclerotic plaques deposited in the arterial wall.
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D. HDL molecules contain higher amounts of proteins and a lower concentration
of cholesterol and lipids, as compared with the other lipoproteins. Their primary
function is to enable secretion of cholesterol from cells, esterification of cholesterol in
plasma and relocating it to other lipoproteins, and the return of cholesterol to the
liver from peripheral tissues for excretion. This process is known as ‘reverse
cholesterol transport’ (RCT) and has the ability to protect against excess cholesterol
accumulation and oxidative damage (Figure 1.2) [8]. Moreover, HDL cholesterol is
thought to have antioxidative, anti-inflammatory, anticoagulation, platelet antiaggregatory, and profibrolytic effects [9], which can alleviate the harm generated by
increased levels of LDL cholesterol.
The nascent HDL particles are synthesized in the extracellular space of the small
intestine and liver as protein-rich molecules. Apo A1 is the major protein component
of HDL in plasma. The protein promotes cholesterol efflux from tissues to the liver for
excretion, and it is a cofactor for lecithin: cholesterol acyltransferase (LCAT), which
is responsible for the formation of most plasma cholesteryl esters. A specific
transporter molecule, ATP-binding cassette transporter, sub-family A, member 1
(ABCA1) facilitates the transfer of phospholipids and cholesterol to lipid-poor
apolipoproteins, especially Apo A, in the nascent HDL particles. Increased levels of
ABCA1 imply that an organism may resourcefully collect cholesterol deposits from
arterial walls and transport it back to the liver.

7

Figure 1.2 HDL/ Reverse Cholesterol Transport Pathway
Abbreviations: ATP-binding cassette transporter, sub-family A, member 1, ABCA1;
ATP-binding cassette sub-family G member 1,ABCG1; Cholesteryl ester transfer
protein, CETP; High density lipoprotein, HDL; Lecithin-cholesterol acyltransferase,
LCAT; Low density lipoprotein, LDL; Low density lipoprotein receptor, LDL-R;
Scavenger receptor class B1, SRB1 [8]
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In order for RCT mechanism to function properly, HDL has to bind to the
receptors on the extra-hepatic and hepatic cells. Through its Apo E component, HDL
is able to attach to LDL receptors in addition to HDL receptors. Hence, at its receptor
site, HDL is able to compete with LDL. Another key molecule involved in RCT is
scavenger receptor class B1 (SRB1), which has the ability to increase HDLmediated cholesterol efflux. SRB1 functions in hepatocytes to cleave cholesterol
esters off transporter molecules; hence they can be re-metabolized by the liver.
In addition, cholesterol esters of HDL can be transferred to VLDL and LDL by the
action of cholesterol ester transfer protein (CETP). This enzyme allows for excess
cellular cholesterol to be returned to the liver by the LDL-receptor pathway [10], as
cholesterol esters can be exchanged for TG by CETP from Apo B containing
lipoproteins to HDL and vice versa. Overall, in this process, cholesterol is removed
from the peripheral tissues and carried to the liver. About 30% of the serum
cholesterol is carried during the RCT process [1]. Thus, within the vascular
endothelium, if the quantity of cholesterol deposited is reduced, the risk of
atherosclerosis and formation of fatty plaque is also reduced.
1.3 Risk Factors
With respect to heart disease, as with any chronic illness, there are several risk
factors-modifiable and non-modifiable- linked to the development and progression of
CVD. The major non-modifiable factors, which cannot be changed, include genetic
alterations, family history, increasing age, gender (men have higher risk), post
menopausal, and race (African Americans, Hispanics, native Indians and Hawaiians,
and some Asians have increased risk when compared with Caucasians). The major
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risk factors that one can modify, treat or control by lifestyle modifications and/or
medicine include diabetes, high blood pressure, poor diet and sedentary routine,
obesity, smoking, stress, and abnormal levels of blood lipids (partially modifiable, not
related to genetic aberrations). A combination of any two or more of the risk factors
highly increases the development of atherosclerosis and other related coronary
disease.
1.3.A Diet
Diet is an important determinant of chronic disease risk, particularly heart
disease. It represents a significant component of any strategy to achieve population
level reductions in the burden of CVD. Although drug treatment, such as lipidlowering statin drugs, may be necessary among individuals at high risk of CVD or
with genetic alterations, adoption of a healthy diet is the preferred method in the
general population in order to prevent or delay the onset of the disease.
The primary dietary determinants of hypercholesterolemia are fats, in particular,
saturated and trans fatty acids, and dietary cholesterol. Over the last few decades,
various studies have confirmed that the level of saturated versus unsaturated fatty
acids in one’s diet can play a direct role in CVD [11]. Valuable results were
published from the epidemiological studies of the seven countries [12], the
Framingham studies [13], as well as the Japanese individuals migrating from Japan
to Hawaii and California [14]. All of these investigations demonstrated the
environment’s influence on plasma cholesterol levels, in particular the impact of the
relative levels of saturated versus unsaturated fatty acids in one’s diet. Several other
studies have also experimented with the substitution of various fats to observe the
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outcome on plasma cholesterol levels. It was noted that when polyunsaturated fatty
acids were substituted for saturated fatty acids, patients experienced reduced
plasma cholesterol levels, and had a decreased rate of death and repeat myocardial
infarctions [15, 16].
In addition, while Brown and Goldstein [17] are mostly famous for their work on
mechanistic action of LDL receptors, they have also researched the mechanisms
behind the effects of unsaturated fatty acids to lower plasma cholesterol levels.
Transcription factors, such as sterol response element binding proteins (SREBP)
raise cholesterol, fatty acid, and LDL receptor biosynthesis. SREBP transcription
and SREBP precursor proteins are reduced when unsaturated fatty acids are
present in the diet. Additionally, another mechanistic process of certain unsaturated
fatty acids is to control peroxisome proliferator activated receptor alpha and
carbohydrate regulatory element binding protein/Max-like factor X function, which
can result in decreased concentration of plasma lipids [18-20], and may also
influence lipoprotein catabolism independently of the LDL receptor [21].
Like the role of dietary fat in regulating plasma cholesterol levels, the importance
of dietary cholesterol absorption in regulating plasma and body cholesterol
homeostasis has been shown in numerous epidemiological and clinical studies.
Populations consuming dietary cholesterol less than 100 mg per day along with lowfat diets have low LDL cholesterol levels and low incidence of coronary disease [22,
23]. The National Cholesterol Education Program guidelines recommend dietary
cholesterol to not exceed more than 300 mg per day.
1.3.B Obesity
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Excess adiposity and obesity are the root cause of numerous diseases, which
contribute to a considerable lifelong morbidity and are highly linked to cardiovascular
mortality. The rapid increase in obesity prevalence is most of the time not due to
genetic modifications, but rather is a societal disparity between physiology and
environment, due to abundance of food and a sedentary lifestyle. Obesity, mainly
central obesity, represents a major culprit of the metabolic syndrome, which includes
insulin resistance, hypertension, diabetes mellitus, non-alcoholic fatty liver disease,
and dyslipidemia, all risk factors for development of CVD [24, 25].
The risk relationship between obesity and atherosclerosis was seen in young
men (15 to 34 years old) in the PDAY study [26], as well as in an older population
(35 to 54 years old) [27], suggesting that risk factors such as obesity, may operate
continuously as atherosclerosis progresses. Among the traditional risk factors, the
dyslipidemia may to some extent be attributable to the increased release of free fatty
acids from adipose tissue, which may consecutively increase very low density
lipoprotein (VLDL) production and plasma triglycerides (TG). The release of free
fatty acids may also contribute to insulin resistance, which has been highly
associated with atherogenic pro-inflammatory and pro-oxidant vascular alterations
[28, 29].
Apart from atherosclerosis, heart failure is also more prevalent among obese
patients, possibly due to the expansion of the blood volume associated with
expanded adipose tissue mass. Frequently, when hypertension is associated with
obesity, it can contribute to left ventricular hypertrophy and ultimately heart failure.
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These correlations warrant future research to learn about the impact of the
increased adipose tissue accumulation on cardiovascular pathophysiology.
1.3.C Hypertension
Hypertension is one of the most common disorders worldwide and it ranks as the
leading chronic risk factor for mortality, accounting for 13.5% of all deaths [30]. High
blood pressure is responsible for half of all strokes and ischemic heart disease, and
can affect many other CVD, including atherosclerosis, CHD, and renal disease.
Moreover, in overweight patients the negative impact of hypertension on CVD is
more significant as compared with normal weight individuals [31].
A diet high in sodium and low potassium represents the most important
environmental factor affecting hypertension. The American population consumes an
average of more than 6 g of sodium daily and more than one third of the population
has hypertension [17]. In contrast, in communities were the sodium intake is less
than one gram per day, the prevalence of hypertension is about 1 % of that in
industrialized societies.
The American Heart Association set the recommendations for sodium and
potassium consumption based on the DASH study (Dietary Approaches to Stop
Hypertension), which represents a diet based on grains, low-fat dairy, fish and
poultry, and rich in fruits and vegetables. The DASH study showed that the blood
pressure was reduced in subjects following this diet, as compared with the average
American diet [32].
1.2.D Dyslipidemia
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Abnormal lipoprotein metabolism is often observed as a secondary effect of
diabetes mellitus, obesity, hypothyroidism, or kidney disease, while only few
individuals carry inhered defects in lipoprotein metabolism, such as hyper- or
hypocholesterolemia. The term dyslipidemia refers to abnormal plasma lipid levels,
including hypercholesterolemia (increased levels of serum LDL cholesterol),
hypertriglyceridemia (increased levels of TG), and low levels of high-density
lipoprotein (HDL) cholesterol. The combination of low HDL cholesterol, high LDL
cholesterol, and hypertriglyceridemia is referred to as the lipid triad, and along with
other non-lipid risk factors comprise the metabolic syndrome, which is

highly

correlated to increased risk for CVD [33]. Accordingly, the TC to HDL cholesterol
ratio is a more significant predictor of risk than TC alone [34].
The role of lipoproteins in the metabolism of TG and cholesterol in relationship to
CVD has been highly discussed over the last decades. Numerous epidemiological
studies have shown that high concentrations of plasma TC and LDL cholesterol are
associated with an increased risk for atherosclerosis [35]. A meta-analysis
conducted on 90,000 patients showed that 1 mmol (39mg/dL) reduction in the
concentration of LDL cholesterol resulted in a 23% reduction in cardiovascular
events [36].
The Framingham Heart Study was a significant project that revealed the
association between development of CVD risk and plasma lipid abnormality. This
study began in 1948 and monitored over ten thousand subjects that had several risk
factors for CVD, in particular an abnormal blood lipid profile [34]. Since the first
results of the Framingham Heart Study were published, various trials have been
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conducted to analyze the impact of these factors on occurrence of CVD, with an
emphasis on serum cholesterol levels [1].
Over the last decade, there have been various advancements to control and
minimize the risk and incidence of CVD, particularly enhancing and monitoring
plasma lipid profiles. The Adult Treatment Panel (ATP) has been set up by the
National Cholesterol Education Program (NCEP) to provide guidelines for
maintaining optimal cholesterol levels. ATP III, originally published in 2002 and
updated in 2004, is the most current panel as warranted by advances in the science
of cholesterol management [1].
Apart from TC and LDL cholesterol, numerous epidemiological studies suggest
that low levels of HDL cholesterol (<1.0 mmol/L or 40mg/dL) represent a significant
risk factor for cardiovascular events, independent of LDL cholesterol levels [37],
whereas high levels of HDL cholesterol act as a protective agent against CVD [38].
A decrease in HDL cholesterol levels can be due to one or a combination of the
known non-modifiable risk factors (e.g. genetic aberrations) or the modifiable risk
factors, such as obesity, malnutrition, and different drugs, like anabolic steroids,
beta-blockers, progestins, and isotretinoin [1]. It has also been shown that often a
low HDL cholesterol level is associated with an increase in TG level. This high TG low HDL cholesterol combination, in part also explains the risk generated by
abdominal obesity. Due to the low-high state of HDL cholesterol and TG levels,
respectively, this combination is characteristic of insulin resistance syndrome, and
provides a link between obesity, diabetes, and dyslipidemia.
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1.4 Current Therapies
1.4.A Statin Drugs
Since a major risk factor for CVD is elevated LDL cholesterol, numerous studies
have been conducted to identify methods to lower this lipoprotein. Most common
therapy used for lowering LDL cholesterol focuses on hydroxyl-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, also known as statins [1]. This class
of drugs was developed to compete with HMG-CoA for binding at the catalytic site of
HMG-CoA reductase and therefore to decrease the synthesis of cholesterol [39].
There are several statins on the market that are widely prescribed for
hypercholesterolemic patients to achieve guideline-recommended LDL cholesterol
goals and can reduce the risk of initial and recurrent cardiovascular disease by 2030 % [40].
However, statins are known to cause severe adverse effects such as heartburn,
diarrhea, flatulence, nausea, vomiting, headache, rhabdomyolysis, myalgia,
myositis, and raised level of liver enzymes [1]. Also statins are not suitable for
patients with increased levels of serum transaminase, active liver disease, or if
pregnant or lactating. Also, interaction with other medications needs to be closely
monitored when therapy with statins occurs for extended periods of time [1].
1.4.B Bile Acid Sequestrants Agents (BASA)
Bile acid sequestrants agents (BASA) are another class of drugs for decreasing
the levels of LDL cholesterol. They generally work by interfering with the
enterohepatic recirculation. Bile acid sequestrants bind bile acids in the gut, forming
insoluble complexes which are excreted. By blocking enterohepatic recirculation and
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diminishing the liver of ready-made bile acids, the liver increases synthesis of
cholesterol and up-regulates LDL receptors, which results in increased clearance of
LDL cholesterol from the systemic circulation. As a new generation of BASA therapy,
Colesevelam is considered to be a high-capacity agent, with four to six times
increased potential as compared with older BASA. It can reduce LDL cholesterol in a
dose-dependent manner [41]. Although the side effects are somewhat of a lesser
degree as compared with the old generation of BASA, some gastrointestinal
distress, such as abdominal pain, constipation, heartburn, and bloating does occur.
1.4.C Cholesterol Absorption Inhibitors (Ezetimibe)
Ezetimibe, similar to BASA, blocks the exogenous pathway of cholesterol
metabolism and can lower LDL cholesterol to a similar extent as Colesevelam. It
works by inhibiting the absorption of ingested cholesterol by about 50% [42].
However, because Ezetimibe is extensively metabolized in the liver and it is
systemically absorbed, there are concerns with regards to the safety of
administering the drug during pregnancy, to nursing mothers and children, and other
patients with impaired liver function. Some of the noted side effects associated with
Ezetimibe include gastrointestinal distress, headache, fatigue, and myalgia.
1.4.D Niacin
Niacin (Nicotinic acid) is a well known therapy to increase HDL cholesterol, while
decreasing the LDL and TC in plasma. Niacin inhibits the release of free fatty acids
from adipose tissue and the production of TG in the liver. In addition, niacin also
directly

inhibits

the

hepatocyte

microsomal

diacylglycerol

acyltransferase-2

(DGAT2), the key enzyme involved in the conversion of diacylglycerol to
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triglycerides. Decreased synthesis of TG results in intrahepatic degradation of Apo
B, with less VLDL available to produce LDL cholesterol. Moreover, niacin can
decrease the size of the VLDL particle, which affects the rate of exchange of TG for
cholesterol mediated by CETP. The acquired excess triglycerides in the large LDL
particles undergo rapid hydrolysis by hepatic lipase, which leads to the formation of
small dense LDL particles.
Thus, the goal of niacin therapy is to reduce LDL and TC levels, as well as
increase levels of HDL cholesterol, overall improving the lipoprotein plasma profile.
However, multiple adverse effects, such as nausea, abdominal pain, flushing, and
pruritus have been reported, and the poor patient adherence make this a non
desirable drug. Furthermore, several clinical studies have advised that therapy
involving nicotinic acid in high doses caused glucose intolerance in patients with
abnormal glucose metabolism [43], as well as high toxicity levels and gastrointestinal
disturbance [40]. Nicotinic acid therapy has also been found to decrease insulin
sensitivity and increase plasma glucose levels [44, 45].
1.4.E ApoA1 Milano Complex
The importance of Apo A1, the main structural protein of HDL (70%) has been
well established, as it plays a major role in RCT, removing cholesterol from
macrophages and returning it to the liver for excretion in bile. Previous animal
studies have shown that augmenting Apo A1 increases HDL cholesterol levels and
decreases atherosclerosis and cardiovascular events [1]. The recent research
studies investigated a recombinant Apo A1 Milano complex, which was shown to
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increase HDL cholesterol levels in patients with acute coronary syndrome [46], but
this is an invasive treatment requiring intravenous dosing.
Other Apo A1 targeting therapies are under investigation, including synthetic
peptides such as L-5F, D-4F, and ETC-642, which are intended to imitate the
favorable effect of Apo A1 in promoting cholesterol efflux from macrophages,
decrease inflammation, and progression of atherosclerosis [47-50]. However, the
application of these peptides is limited since the administration of the treatment is
intravenous, and the peptides have a complex structure and are very expensive to
produce. Therefore, a different approach to increase Apo A1 remains to be
discovered.
Recently, several new therapies targeting lipoproteins have been applied in
clinics, either as monotherapy or in combination with statins, but severe side effects
and poor outcome warrant more research. A recent analysis showed that during
1999-2006 the prevalence of hypercholesterolemia and related factors remained
stationary among the US population, despite the increase in usage of cholesterol
lowering medications [51].
Thus there is an acute need for a new therapeutic approach that can reduce the
circulating cholesterol levels and improve the HDL/LDL cholesterol ratio significantly,
without the incurrence of adverse effects. It has been suggested that LDL and HDL
cholesterol should be adjusted simultaneously in order to prevent CVD. The risk for
a cardiovascular event can be decreased by nearly 1% for each1% reduction in LDL
and by more than 1% for each 1% increase in HDL, suggesting that improvement in
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both lipoprotein fractions has a synergistic effect as compared with either lipoprotein
alone [52].
There is also a further need of replacing current statin therapy and regulating
cholesterol at a gene signaling level, which the new emerging therapies are
targeting. Many studies are underway to identify new choices for therapies that can
decrease the LDL cholesterol, while increasing the HDL cholesterol with minimal
side effects. One of the targeted therapies currently being studied is inhibition of
CETP [40]. Promising results were obtained by partial inhibition of CETP [1], and if a
suitable drug can be formulated, this therapy can be successful in clinical
management of hypercholesterolemia.
1.4.F Omega-3 Polyunsaturated Fatty Acids
Over the last decade, several other treatments intended to improve the lipid
profile have been developed, especially naturally derived as food supplements.
Omega-3 polyunsaturated fatty acids can reduce the production and secretion of
VLDL particles, and increase TG removal from VLDL and chylomicron particles via
the upregulation of lipoprotein lipase. Several studies have shown that when doses
higher than 3g/day of omega-3 fatty acids were administrated, TG were reduced by
32% [53, 54]. However, not enough statistics are known about the decrease in CVD
risk, especially in woman, since most studies on fish consumption and omega-3 fatty
acids were conducted in men. Also, the overall lipid profile was improved only when
omega-3 fatty acids supplements were given in combination therapy with statin
drugs, reducing some major coronary events in patients followed for 4.6 years [54].
1.4.G Other Natural Compounds
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Since most synthetic drugs designed to treat hypercholesterolemia have so far, a
low success rate in decreasing the rate of cardiovascular events, most therapeutic
interventions include an aggressive change in diet and lifestyle, alone or in
combination with drug therapy. Some approaches include consuming green tea [55],
plant sterols [56], soluble fiber [57], cocoa and dark chocolate [58] have produced
promising results and warrant further investigation.
More recent studies have found that the probiotic bacteria, especially bile salt
hydrolase (BSH)-active probiotic bacteria, have demonstrated their ability to
decrease cholesterol levels in several randomized clinical trials [59-62]. It was
reported that an increased activity of BSH can increase intraluminal bile acid
deconjugation, resulting in raised levels of circulating deconjugated bile salts, which
in turn decrease cholesterol absorption by enterocytes [63, 64]. Various algal and
seaweed extracts have also been studied to determine their ability to decrease
hypercholesterolemia and avoid cardiovascular events. Several scientists have
reported that seaweeds, isolated algal polysaccharides and their water-soluble
fractions demonstrated hypocholesterolemic effects in experimental animals [65, 66].
Recent research conducted by Bocanegra et al showed that the lipoprotein profile of
male Wistar rats was significantly improved when fed freeze-dried algae added to
their diets for 3 weeks, reducing the TC, TG, phospholipids, and protein contents of
the various lipoprotein fractions [67].
1.4.H ProAlgaZyme (PAZ)
PAZ algae infusion is the fermentation product of a blend of freshwater
organisms, including red and green algae [68]. It contains less than 100 ppm of total
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dissolved solids, consisting of a mixture of approximately 90% salts (free of heavy
metals at a detection limit of < 0.1 ppm), while the remaining 10% is a proprietary
mixture of organic constituents. In a preliminary study, Oben et al [68] evaluated the
effects of PAZ on body weight, body mass index, blood lipids, fasting blood glucose
levels, and markers of inflammation in individuals with the metabolic syndrome. The
results showed a significant beneficial outcome on the various parameters analyzed,
including the lipid profile, suggesting that PAZ could be an effective method for
lowering the risk of developing CVD.
1.5 Metabolomics
As observed in recent reports regarding therapies for hypercholesterolemia and
risk for CVD, it was concluded that the lipid profile alone does not provide a
complete picture of the disease progression. Analysis of a multifactorial disease,
such as atherosclerosis and other forms of CVD, using a limited number of
biomarkers can lead to inaccurate diagnosis and treatment regimes, weakening the
advancement of new therapies. In contrary, the omics-based approaches
(metabolomics, in particular) have allowed scientists to characterize, at the
molecular level, complex biological systems and their changes in pathological
processes [69, 70] providing an excellent tool for examining phenotypes using
hundreds of metabolite descriptors.
It has been determined that the human genome encodes approximately 30,000
genes, which are responsible for translating more than 100,000 distinct proteins [70].
The complete set of all chromosomes and genes is referred to as the genome, a
term widely used in research for more than seven decades. However, the ‘omic’
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technology was not introduced until 1986 by Thomas Roderick [71]. The science of
the genomes of organisms was implemented to provide information about the
function of different genes and to compare them among multiple organisms.
Moreover, along with genomics, the science of proteomics signifies the
comprehensive study of proteins produced by an organism during its lifetime based
on its genome. However, the proteome of an organism might change due to several
factors, including cellular environment, biochemical interactions, while the genome
remains constant. Also, newly translated proteins might undergo various
modifications (such as glycosylation, phosphorylation, degradation, alternative
splicing) and might not be part of the cellular processes or the organism’s
metabolism. Thus, it is more accurate to study proteins or metabolites that have
been part of biochemical and cellular processes, providing an accurate state about
the changes within the system under different conditions, including environment,
drugs, disease, and toxicity. These discoveries lead to the emerging field of
metabolomics, the latest ‘omic’ approach, which measures changes in populations of
low molecular weight metabolites under a given set of conditions [72].
Metabolomics is a comprehensive and quantitative study of the complete set of
intracellular and extracellular metabolites produced as an end product of an
organism’s metabolism [70]. This technique can be utilized to investigate the effect
of environmental stress or chemical composition of the organism, metabolite pattern,
effect of a drug, or disease progression. The analysis can be performed using cells,
tissues, body fluids, such as urine, saliva, plasma, and tears [73], having the option
to perform it as a non-invasive procedure. One of the important attributes of
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metabolomics is the possibility of identifying a molecule or a set of molecules
responsible for changes in the physiology of an organism under a particular stress.
Metabolite profiles can be regarded as key indicators of normal phenotype and
pathology, providing novel information about new biomarkers, drug interactions,
toxicological insult, nutritional status, and the effects of these factors on the genome.
The human metabolome is directly influenced by exogenous (such as diet, drugs,
physical status, and stress) and endogenous factors (such as body composition,
age, gender, and health status), which vary amongst individuals (Figure 1.3).
Metabolomics technology can bring new insight into personalized medicine and
might help answer questions related to specific metabolites by integrating or
connecting different biochemical pathways. Qualitative and quantitative metabolomic
analyses provide a view of the biochemical status of an organism at a definite time,
under specific conditions. Thus, the extension of this technology to human medicine
and human nutrition offers enormous potential, with the possibility of linking
metabolomics with the wider elements of nutrigenomics.
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Figure 1.3 Exogenous and Endogenous Factors Likely to Influence the Human
Nutritional Metabolome [74]
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1.6 Nuclear Magnetic Resonance and Mass Spectroscopy
Since the majority of the metabolites are present virtually in all tissues and fluids,
the concentration of the metabolites is the major factor that distinguishes different
phenotypes [75]. Therefore, the techniques to analyze the samples and process the
acquired data must be highly specific and accurate. At present, with rapid advances
in analytical chemistry technologies, including nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS), the capacity of accurately identifying
small metabolites has become easier.
There are different types of MS techniques that can be used, including time-offlight (TOF) MS, tandem quadruple (TQ) MS, which can be combined with liquid
chromatography, gas chromatography or capillary electrophoresis, as a useful
analytical tool for metabolomics [76-78]. While MS technology is more sensitive as
compared with NMR, the disadvantage is that MS does not confer a uniform
detection, caused by variable ionization efficiency. Also, MS based techniques
require extensive preparation of the sample before analysis, such as extraction and
derivatization, which can alter the composition of the sample and can lead to invalid
data and conclusions [79].
The NMR technique is based on the magnetic properties of atomic nuclei, usually
hydrogen nuclei (1H NMR), but

13

C, 31 P, 15 N, and
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F are also commonly used. The

identification of different atomic nuclei is based on their resonance frequencies,
which are dependent on their locations or environment in the molecule [80]. The
intensity of the NMR spectrum changes linearly with the concentration of the
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compound present. [81]. Thus, signal intensities give direct information about the
relative concentrations of different compounds in a complex mixture.
The major advantage of using NMR spectroscopy is its high reproducibility (>
98%), ability to analyze both liquid and solid samples, tissues and cell extracts [82],
and it can help in the identification of unknown metabolites. NMR spectroscopy can
fingerprint an entire biological sample, requiring minimum sample size and sample
preparation time, while evaluating the entire metabolic status of an organism. 1H
NMR metabolomics approach has been largely used with great success in
identification of biomarkers and monitoring the effects of biological stressors [83],
and more recently it has become an important tool for diagnosis and treatment of
chronic diseases, such as obesity, diabetes and CVD [2].
An innovative study conducted by Brindle et al in patients with CVD identified
characteristic

plasma

metabolites

that

were

different

in

individuals

with

angiographically normal coronary arteries [84]. This discovery could displace the
necessity to perform angiography, an invasive and time consuming procedure.
Comparing patients with triple vessel disease with controls, this metabolomics
technique was able to predict the presence of coronary disease with a specificity of
93% and a sensitivity of 92% [84]. However, when these data were reproduced, after
normalization by gender and statin drug therapy, it was shown that it can only predict
for 61% of the patients [85]. Still, while 1H NMR is considered a poor predictor on a
per sample basis, perturbations in specific metabolites associated with the metabolic
syndrome have been identified. Numerous studies have followed and acknowledged
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changes in plasma profiles, in particular associated with alterations in the lipoprotein
particles, insulin resistance and atherosclerosis [86-88].
Metabolomics, despite the smaller expected size of the metabolome, compared
with the other ‘omics’ approaches, generates an enormous quantity of data. Analysis
and interpretation is a critical step that could otherwise lead to erroneous
conclusions. Thus, the choice of the most appropriate statistical analysis is crucial, in
order to extract the maximum amount of accurate biological information from the
data set. Although, the area of developing sophisticated statistical tool is still in
progress, a number of techniques are available.
1.7 Multivariate Data Analysis (MVDA)
MVDA is a powerful tool for the analysis of data sets containing a large number
of variables. It visualizes the correlation between variables in complex or large data
sets (e.g., thousands of signals in NMR spectra) in relation to a target variable such
as disease status, diet intervention, or environmental influence.
Principal Component Analysis (PCA)
PCA is a multivariate projection method designed to extract and display the
systemic variation in the data matrix X (the table of integrals from NMR plasma
samples). This is an unsupervised analysis, which implies that the software has no
prior knowledge about the data matrix [89]. This method enables differentiation
between samples based on their metabolites composition. In PCA, the data sets of
related large variables are transformed into small uncorrelated variables known as
principle components (PC). This transformation is defined so that the first PC has
the largest possible variance (accounts for as much of the variability in the data as
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possible), and each succeeding component has the highest variance possible under
the constraint that is orthogonal to the preceding component.
The data set is visualized as a PCA score plot, where each score represents one
observation, such as one NMR spectrum (one sample/animal). The observations will
be grouped together or scattered based on the similarities and/or dissimilarities in
their metabolomic profile. The contribution of each individual variable to PC can be
calculated as a loading plot. The corresponding loading plot will provide information
about the part of the spectrum that is responsible for the similarities and/or
dissimilarities in the data set. The specific region of the spectrum that is responsible
for the separation between the groups can be located using this method.
Partial Least Square (PLS) and PLS- Discriminant Analysis (PLS-DA)
PLS is a regression extension of PCA, which is used to connect the information
in two blocks of variables, X and Y. The data from the metabolomics analysis (X
parameter) can be correlated with other independently measured factors (e.g. total
cholesterol, HDL cholesterol, gene expression) keeping these factors as Y
parameters. PLS helps to determines whether or not a correlation exists between the
two data sets, which otherwise would be considered unrelated.
In PLS-DA the data set is distributed into classes and its objective is to find a
model that separates the classes of observation on the basis of their X-variables,
while using a hypothetical Y-variable. Both of these methods of analysis are
supervised, which implies that some information about the data set is provided to the
software prior to analysis [89]. Taken together, PCA, PLS and PLS-DA give valuable
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information about the variability and/or similarity of large data sets, which otherwise
will be an impossible task using standard statistical tools.
1.8 Metabolite Identification and Quantification (Chenomx)
Chenomx software represents a metabolite database that helps to identify and
quantify the concentration of the metabolites by comparing the acquired data set or
NMR signal intensities to pre-existing signals from a library of compounds with
known concentration. While MVDA identifies the areas of the spectrum responsible
for similarities and/or dissimilarities between the groups, it is important to identify the
metabolites represented by the spectral regions or peaks in question.
The corresponding metabolites within that range can be easily identified using
Chenomx NMR 7.6 software (Chenomx Suite, Alberta, Canada). This software uses
targeted profiling to reduce analysis time, combining advanced analysis tools with a
compound library of more than 300 common metabolites. Targeted profiling can be
applied to any NMR spectra of virtually any complex mixture, including urine, blood
plasma, saliva, and various cell extracts. Chenomx is MVDA independent, but it is
faster and easier to use once the peaks responsible for the separation between
groups are identified [81].
Profiling of the NMR spectra is accomplished using the Profiler module.
Essentially, a Lorentzian peak-shaped model of each reference compound is
generated from the database information and superimposed upon the actual
spectrum. The linear combination of all modeled metabolites gives rise to the total
spectral fit, which can be evaluated with a summation line. Once the changes in
metabolite concentrations have been determined, the pathways affected by the

30
respective metabolites can be identified using online Kyoto Encyclopedia of Genes
and Genomes (KEGG) database (http://www.genome.jp/kegg).
Therefore, the metabolite profiling technique has the potential to become an
essential tool in medicine, which can be applied for diagnosis and treatment of any
disease. Metabolites can be detected based on any of their physiochemical or
biological properties, and they can be used as early biomarkers to distinguish
between healthy and diseased state, toxicity levels, nutritional interaction or other
factors. Metabolomics approach is a relatively new field in medicine and
pharmacology, but reveals great promise, which potentially will allow for better
understanding of human diseases, including CVD.
For decades, numerous scientists across the globe have been investigating the
etiology of atherosclerosis and the occurrence of cardiovascular events, such as
stroke and myocardial infarction. Despite considerable improvements in therapeutics
of cardiovascular disease, epidemiological data reveal that the mortality rates
associated with the disease are still on the rise. Recent developments have
suggested that identifying the changes in the metabolite profiles will grant a higher
degree of understating of the disease. Because of its excellent capability to analyze
the metabolome, metabolomics provides a much more comprehensive assessment
of patient’s health status, in comparison with the measurement of particular
metabolites. This approach makes metabolomics a great technique for the
identification, quantification, and development of biomarkers.
1.9 Aims of Study
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The aim of the present study is to document the potential effect of PAZ and its
subfractions on plasma lipid concentrations in a hypercholesterolemic hamster
model. In a preliminary study, Oben et al [68] evaluated the effects of PAZ on body
weight, body mass index, blood lipids, fasting blood glucose levels, and markers of
inflammation in individuals with the metabolic syndrome. The results showed a
significant beneficial outcome on the various parameters analyzed, including the lipid
profile, suggesting that PAZ could be an effective method for prevention of CVD.
However, some inconclusive results were reported by Oben et al [68], such as
exceptionally large changes observed between week 8 and 10, with some subjects
experiencing about a two-fold increase in HDL cholesterol. In addition no measures
of TG or LDL cholesterol were reported at 10 weeks.
Thus, this study evaluates the efficacy of PAZ as a preventative and therapeutic
agent in an animal model. Male Golden Syrian hamsters were selected as the
experimental model since they have been used extensively to study human
lipoprotein metabolism [90, 91]. It has been noted that in both humans and
hamsters, the liver has a low rate of cholesterol synthesis and it is the main site for
plasma LDL cholesterol clearance [92].
Hypothesis
The study hypothesizes that PAZ and/or its subfractions would effectively
improve the plasma lipoprotein profile. In addition, it is hypothesized that the change
in the plasma metabolomic profile due to PAZ intervention will reflect the
improvement in the plasma lipid profile.
The following specific aims were undertaken to test the hypothesis:
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AIM 1: To determine the biological activity of complete PAZ and its
subfractions in a hypercholesterolemic animal model
The objective of this aim was to test the effectiveness of PAZ and its subfractions
as a preventative agent in a high fat induced hypercholesterolemic hamster model.
For this, PAZ and its subfractions were administrated as part of drinking fluid along
with the dietary (high fat) regimen. Eighty male Golden Syrian hamsters were
randomized into control (n=20; control diet) and treatment groups (n=60; high fat diet,
30% calories from fat). Further, the control group was subdivided into water (CW) or
PAZ (CP) groups (n=10), based on their drinking fluid. The treatment group was
subdivided into 6 groups (n=10): HW (water), HP (complete PAZ), HF1, HF2, HF3,
HF4 (4 different subfractions of PAZ obtained by sequential affinity gel
chromatography). After 4 weeks of treatment, animals were sacrificed and blood was
collected by cardiac puncture. Hepatic mRNA was extracted and analyzed to
determine if there were changes in the gene expression related to HDL cholesterol
metabolism.
AIM 2: To investigate the change in plasma metabolomic profiles upon
administration of PAZ and the biologically active fraction (BAF)
Plasma metabolomic profile using 1D proton NMR was performed to determine
the changes in metabolite concentrations among animals that received water
(control), complete PAZ, and the fraction found to be biologically active in Aim1. Data
were analyzed using multivariate data analysis SIMCA P+ software. Targeted
profiling was applied to NMR spectra to determine the metabolites that are different
between the groups of interest. Once these metabolites had been identified and
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quantified (Chenomx), analysis of the pathways involving the specific metabolites
was conducted. In addition, metabolomic profile was correlated with the plasma lipid
profile.
AIM 3: To determine the therapeutic effect of the biologically active fraction on
hypercholesterolemia
The goal of this aim was to determine if plasma lipid profile of animals in a
hypercholesterolemic state can be improved upon treatment with the fraction found to
be biologically active in Aim 1. Secondly, this part of the study aimed to determine the
time course required for the therapeutic effect on lipid parameters.
Fifty male Golden Syrian hamsters were fed a high fat diet for 4 weeks prior to
receiving treatment with the biologically active fraction found in Aim 1. Group HW
from Aim 1 was considered as group T0 (T = treatment) for this study and served as
control, i.e. animals on high fat diet and water alone. The remaining 40 animals were
randomized into 5 groups: T3, T7, T10, T14, and T21, and received the biologically
active fraction for 3, 7, 10, 14, and 21 days, respectively, as their drinking fluid. Each
group was sacrificed following the same procedure as in Aim 1 for blood and tissue
collection. Further, hepatic mRNA was extracted and analyzed to determine if there
were changes in the gene expression related to HDL cholesterol metabolism.
AIM 4: To investigate the change in plasma metabolomic profiles upon therapy
with the biologically active fraction
Plasma metabolomic profile using 1D proton NMR was performed to determine
the changes in metabolite concentrations after 21 days of therapy, as compared with
controls. Data were analyzed using multivariate data analysis SIMCA P+ software.
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Targeted profiling was applied to NMR spectra to determine the metabolites that are
different between the treatment group (T21) and the T0 group, which served as
control for this aim. Once these metabolites were identified and quantified using
Chenomx software, analysis of the pathways involving the specific metabolites was
conducted. In addition, the metabolomic profile was correlated with the plasma lipid
profile.
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CHAPTER 2
MATERIALS AND METHODS
2.1 AIM 1: To determine the biological activity of complete PAZ and its
subfractions in a hypercholesterolemic animal model
Rationale: The objective was to test the effectiveness of PAZ and its
subfractions as a preventative agent in a high fat diet induced hypercholesterolemic
hamster model. For this, PAZ and its subfractions were administrated as part of the
drinking fluid along with the dietary regimen. Plasma lipid profile was measured
using enzymatic assays, while lipoprotein distribution was determined by density
gradient ultracentrifugation. Further, hepatic mRNA expression was also analyzed
for potential effects on genes involved in HDL/ reverse cholesterol transport.
2.1.A Animal Protocol and Experimental Design
Eighty male Golden Syrian hamsters (Mesocricetus auratus), LVG strain were
purchased from Charles River Laboratories, Wilmington, MA. Upon arrival they were
8 weeks old and weighed approximately 80 g each. The animals were acclimatized
and given water and laboratory rodent diet 5001(Lab Diet, Richmond, IN) ad libitum
for one week prior to the initiation of the experimental regimen. They were housed
individually in a temperature-controlled room (25°C ) and maintained on a 12-h
light/dark cycle. They were randomly distributed into control (n = 20, receiving control
purified diet, Table 2.1) and treatment groups (n = 60, receiving high fat diet, 30%
calories from fat, Table 2.2). Further, the control group was subdivided into water
(CW) or PAZ (CP) groups (n=10/group), based on their drinking fluid.
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Table 2.1 Composition of the Control Purified Diet
Ingredient

kcal/gm

grams/kg

Casein

3.58

220

Dextrose

3.8

160

Cornstarch

3.6

460.9

L-Arginine

4

1

L-Tryptophan

4

1.1

Cellulose

0

50

Corn Oil
Mineral Mix
(#260001)
Vitamin Mix
(# 360001)

9

60

0

35

3.84

10

Choline Bitartrate

0

2

Mineral Mix contained the following components: 6,000 g/kg Calcium (Ca);
3,100 g/kg Phosphorus (P); 6,100 g/kg Potassium (K); 1,500 g/kg; Sodium (Na);
2,310 g/kg; Chlorine (Cl); 600g/kg Magnesium (Mg); 140 g/kg Iron (Fe); 5.8 g/kg
Copper (Cu); 3.7 g/kg Manganese (Mn); 23.5 g/kg Zinc (Zn); 0.32 g/kg Chromium
(Cr); 1.6 g/kg Iodine (I); 0.20 g/kg Selenium (Se); 0.20 g/kg Fluorine (F); 1.20 g/kg
Cobalt (Co).
Vitamin Mix contained the following components: 2 g/kg Thaimin HCl; 1.5 g/kg
Riboflavin; 0.7 g/kg Pyridoxine HCl; 9 g/kg Niacin; 4 g/kg Calcium Pantothenate; 0.2
g/kg Folic acid; 0.06 g/kg Biotin; 1 g/kg Vitamin B12 (0.1%); 0.4 g/kg Menadione
Sodium Bisulfite; 1g/kg Vitamin A Palmitate; 10 g/kg Vitamin E Acetate; 0.6 g/kg
Vitamin D3; 10 g/kg Inositol; 959.5 g/kg Sucrose. Vitamin Mix was used at rate of
10 g/kg of diet.
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Table 2.2 Composition of the experimental custom purified diet

Ingredient

kcal/gm

grams/kg

Casein

3.58

110

Lactalbumin

3.9

110

Cornstarch

3.6

370.2

L-Arginine

4

2.5

L-Tryptophan

4

0.3

Dyetrose

3.8

175

Cellulose

0

44

Coconut Oil

9

138.6

Soybean Oil

9

1.4

TBHQ*

0

0.028

Cholesterol
Mineral Mix
(#260001)
Vitamin Mix
(# 360001)

0

1

0

35

3.84

10

Choline Bitartrate

0

2

Abbreviation: * TBHQ: Tertiary butylhydroquinone
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The treatment group was subdivided into 6 groups (n=10/group): HW (water), HP
(complete PAZ), HF1, HF2, HF3, HF4 (4 different subfractions of PAZ obtained by
sequential affinity gel chromatography). Figure 2.1 describes the study design for Aim
1. Drinking fluid was given at either 5% (HF1, HF2, and HF3) or 20% (HP, HF4)
concentration (v/v) for 4 weeks. This dose was established based on the previously
reported dose of 4 oz of PAZ per day in humans [68]. Modifications were made to
account for body weight and amount of fluid intake per day in hamsters versus
humans. High fat diet containing 30 % calories from fat (Dyets Inc., Bethlehem, PA)
was used to induce the rapid hypercholesterolemic state in the hamsters. Body
weight, food and water intake were recorded weekly.
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Male Golden
Syrian Hamsters
(n=80)

Control Group
Regular Purified
Diet

CW
(Water)

CP
(PAZ)

Figure 2.1 Study Design for Aim 1

Intervention
Group
High Fat Diet

HW
(Water)

HP
(PAZ)

HF1
(F1)

HF2
(F2)

HF3
(F3)

HF4
(F4)
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Prior to the beginning of the study, PAZ was fractionated by sequential affinity gel
chromatography (Oxford Biomedical Research, Rochester Hills, MI). Complete PAZ
was passed through four chromatography columns (2.7 cm x 23 cm; approximately
90 mL of resin at full capacity) at a flow rate of approximately 6 mL per minute using
a peristaltic pump (Figure 2.2).
Column 1 containing a weak anion exchange resin (diethylaminoethyl cellulose)
captured proteins and on elution resulted in the F1 fraction. Column 2 containing a
strong anion exchange resin (BioRad AG 1-X8) was designed to capture molecules
containing carboxyl groups and other negatively charged functionalities, as well as
negatively charged ions, and the eluate from the column was designated as the F2
fraction. Column 3 was a strong cation exchange column (Dowex Monosphere 88)
intended to capture molecules containing amino groups and other positively charged
functionalities, as well as positively charged ions. Eluate from column 3 was
designated as the F3 fraction.
Column 4 (silica gel 90 C18 reversed phase) was a C18 derivatized column that
binds non polar organic molecules. The eluate from this column was not used in this
study. Instead, the flow through (labeled as F4), which contains relatively few
molecules, including polar but uncharged organic molecules, as well as molecules of
low polarity that were not captured by columns 1, 2, 3, or 4, was assessed for its
effect on hamster lipid profile. The pH of all fractions was measured and adjusted to
an approximate value of 7.0, prior to being administrated to the animals.
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Figure 2.2 Separation of PAZ into Fractions by Sequential Affinity
A
Gel
Chromatography
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After 4 weeks of treatment, animals were sacrificed and blood, liver, and adipose
tissue were collected. Hamsters were fasted for 8 hours and anesthetized under CO2
gas (Metro Welding, Detroit, MI) prior to sacrifice. Blood was collected by cardiac
puncture with syringes previously rinsed in potassium ethylenediamine tetraacetic
acid (EDTA) solution (15% w/v) and kept on ice. Plasma was separated and collected
after centrifugation at 1,000 x g for 15 minutes at 4°C. Liver and adipose tissue were
collected and immediately flash-frozen in liquid nitrogen for subsequent analysis. The
weight of the liver was recorded immediately after harvesting.
2.1.B Plasma Lipid Analysis
Various enzymatic assays were performed on the collected plasma to determine
the changes in the lipoprotein concentrations as a result of PAZ and its subfractions
administration. Plasma TC and TG concentrations were determined enzymatically,
while HDL cholesterol was measured in the supernatant following precipitation with
Mg2+/dextran sulfate (Pointe Scientific, Canton, MI). The concentration of non-HDL
cholesterol was calculated as the difference between the measured TC and HDL
cholesterol, and included as the sum of VLDL, IDL, and LDL cholesterol. Cholinecontaining phospholipids and free cholesterol was also determined enzymatically
(Wako Chemicals USA Inc., Richmond, VA). The cholesterol ester was determined
by taking the difference between the total and free cholesterol values. The detailed
procedures, including modifications to the manufacturer’s protocol are described
below.
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Total Cholesterol Assay
Briefly, 200 µl of 37°C pre-incubated reagent mixed with 2 µl of plasma sample
was incubated for 5 minutes at 37°C and read at 490 nm using KC4 software (EL x
800 microplate absorbance reader, Bio-Tek, Winooski, VT). The reaction was
carried out in a 96-well assay microplate. Calculations were done according to the
formula provided in the manufacturer’s protocol and plasma total cholesterol
concentrations reported as mmol/L.
Triglyceride Assay
Briefly, 200 µl of 37°C pre-incubated reagent mixed with 2 µl of plasma sample
was incubated for 5 minutes at 37°C and read at 490 nm using KC4 software, EL x
800 microplate absorbance reader. The reaction was carried out in a 96-well assay
microplate. Calculations were done according to the formula provided in the
manufacturer’s protocol and triglyceride concentrations reported as mmol/L.
HDL Cholesterol Assay
For separation of HDL cholesterol, a 100 µl of plasma sample was mixed with 10
µl of reagent, and after 5 minutes incubation at room temperature, it was centrifuged
at 2,000 x g for 5 minutes. For determination of the HDL cholesterol concentration, a
96-well assay microplate was used to mix 200 µl of reagent with 10 µl of
supernatant, followed by incubation for 10 minutes at 37°C. The plate was read at a
wavelength of 490 nm using KC4 software, EL x 800 microplate absorbance reader.
Calculations were done according to the formula provided in the manufacturer’s
protocol and plasma HDL cholesterol concentrations reported as mmol/L.
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Ultracentrifugation
The lipoproteins were isolated by density gradient ultracentrifugation, essentially as
stated by Chapman et al [93]. For each group, lipoprotein isolations (x 2) were carried
out using plasma pooled from 4-5 hamsters in 16 x 93 mm ultracentrifuge tubes.
Lipoproteins were isolated using a Beckman SW-40 rotor (Beckman Coulter, Brea,
CA) at 35,000 rpm and 15°C for 46 hours [94]. Follo wing ultracentrifugation, 26 x 500
µl fractions per tube were collected by sequentially pipetting from the top. The total
cholesterol, triglyceride, choline-containing phospholipids, and free cholesterol
concentration in each fraction were measured using enzymatic reagents as
described. The lipoprotein profile and lipoprotein particle size (diameter) for LDL and
HDL cholesterol molecules were determined, using the following formula [95] :
R = (nm) =
1.093 (TG) +1.044 (CE)
0.968 (FC) + 0.97 (PL) + 0.705 (PR)

X (3 X 2.15)

D (nm) = 2R + 2(2.15)
In the above formula, TG , triglyceride mass; CE, Cholesterol Ester mass; FC, Free
Cholesterol mass; PL, phospholipids mass; PR, protein mass; R, radius; D,
diameter.
Phospholipids Assay
Briefly, the color reagent was mixed with the buffer, and 250 µl of the
reconstituted reagent mixed with 5µl of sample was incubated at 37°C for 5 minutes.
The reaction was carried out in a 96-well assay microplate and read at a wavelength
of 570 nm using KC4 software, EL x 800 microplate absorbance reader. Calculations
were done according to the formula provided in the manufacturer’s protocol.
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Free Cholesterol Assay
Briefly, the content of one bottle of color reagent was dissolved in the buffer
solution. 200 µl of the reconstituted color reagent mixed with 10 µl of sample was
incubated at 37°C for 5 minutes. The reaction was c arried out in a 96-well assay
microplate and read at a wavelength of 570 nm using KC4 software, EL x 800
microplate absorbance reader. Calculations were done according to the formula
provided in the manufacturer’s protocol. Further, amount of cholesterol ester was
calculated by subtracting the free cholesterol from the total cholesterol amount.
2.1.C Real Time Polymerase Chain Reaction (PCR) for Gene Expression
Analysis
Total RNA Extraction
Total RNA was extracted from liver tissues using miRNeasy Mini Kit (Qiagen,
Valencia, CA) to determine the changes in the gene expression related to HDL
cholesterol metabolism. Briefly, 25 mg of previously flash frozen liver tissue was
homogenized in 700 µl lysis reagent provided by the kit. After 5 minutes, 140 µl of
chloroform was mixed in the tube, following by centrifugation at 12,000 x g for 15
minutes at 4°C. The upper aqueous phase was removed , and 525 µl of 100%
ethanol was added to the tube. The mixture was then transferred into the RNeasy
Mini columns. RWT and RPE buffers (provided by the kit) were added to the column
and eluted via centrifugation at 8,000 x g. The total RNA was eluted with 40 µl
RNAase free H20 and centrifuged at 1,000 x g for 1 minute. It was stored at -80°C
until further use.
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Total RNA to cDNA Preparation
In summary, 0.4 µg of total RNA was further subjected to reverse transcription
using the High-Capacity RNA-to- cDNA Master Mix kit (Applied Biosystems,
Carlsbad, CA). The reaction was carried in a total of 20 µl mixture (4ul of Complete
Master Mix, 8 µl of total RNA, and 8 µl of nuclease-free H2O) in Master cycler
(Eppendorf, Hauppauge, NY). The program was set for 5 minutes at 25°C, 30
minutes at 42°C, 5 minutes at 85°C, and 1 hour at 4 °C. The obtained cDNA was
further used to perform quantitative PCR to determine the alteration in the gene
expression due to the diet and treatment intervention.
Real time RT-PCR Analysis
A total of 2 µl of cDNA was used for each real-time RT-PCR reaction using
SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) and MX3005P
instrument (Strategene, Santa Clara, CA) to determine the relative transcription
levels of specific genes (ABCA1, ApoA1, CETP, and SRB1) involved in HDL/reverse
cholesterol transport metabolism.

The cycle conditions were: 10 min at 95°C

followed by 40 cycles of incubation at 95°C for 15s each, then 60°C for 1 min.
Optimization of primer concentration was performed prior to the experiment to avoid
accumulation of nonspecific products or primer-dimers. Likewise, non-template
control (NTC) wells were added to the plate for the same reason. Data were
analyzed according to the comparative threshold (Ct) cycle method and normalized
by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in each
sample. Levels of gene expression were reported as fold differences compared with
hamsters fed the high fat diet and water.
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Table 2.3 Real time RT-PCR Primers
Gene

Primers

Reference

CETP

F:5’-AAGGGTGTCGTGGTCAGTTCT-3’
R: 5’-ACTGATGATCTCGGGGTTGAT-3’

[96]

Apo A1

F: 5’-ACC-GTT-CAG-GAT-GAA-AAC-TGT-AG-3’ [97]
R:5’-GTG-ACT-CAG-GAG-TTC-TGG-GAT-AAC-3’

SRB-1

F:5’- AAG-CCT-GCA-GGT-CTA-TGA-AGC-3’
R:5’- AGA-AAC-CTT-CAT-TGG-CTC-CCT-A-3’

ABCA1

F:5’-ATA-GCA-GGC-TCC-AAC-CCT-GAC-3’
[98]
R: 5’-GGT-ACT-GAA-GCA-TGT-TTC-GAT-GTT-3’

[97]

Abbreviations: CETP, Cholesteryl ester transfer protein; Apo A1, Apolipoprotein
A-1; SRB1, Scavenger receptor class B member 1; ABCA1, ATP-binding cassette
transporter A1
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2.1.D Statistical Analysis
All data were expressed as the mean ± standard error (SE). Differences between
the control and treatment groups were determined using one-way analysis of
variance tests (IBM SPSS Inc, Chicago, IL). The data were analyzed to determine
the effect of the algae infusion relative to distilled water, while the animals were fed
the high fat diet. Statistical significance was defined as P < 0.05.
2.2 AIM 2: To investigate the change in plasma metabolomic profiles upon
administration of PAZ and the biologically active fraction
Rationale: Plasma metabolomic profile using 1D proton NMR was performed to
determine changes in metabolite concentrations among animals that received water
(HW), complete PAZ (HP), and the biologically active fraction found in Aim 1. Data
were analyzed using multivariate data analysis SIMCA P+ software. Targeted
profiling was applied to NMR spectra to determine the metabolites that are present in
different concentrations between the analyzed groups. Once these metabolites had
been identified and quantified using Chenomx software, analysis of the pathways
involving the specific metabolites was conducted.
2.2.A Sample Preparation
Plasma samples (from Aim 1) previously stored at -80°C were thawed and
centrifuged at 9,000 X g for 3 minutes. Samples were diluted with deuterium oxide
(D2O) for proper optimization of the concentration. To these diluted samples a
reference buffer (NMR solvent) solution of 5 mmol/L disodium-2,2-dimethyl 2 –
silapentane-5-sulphonate (DSS) and 10 mmol/L imidazole in D2O (Sigma-Aldrish,
Mississauga, ON) was added in a 9 : 1 ratio (9 parts of diluted plasma sample : 1
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part NMR solvent). DSS was used as spectral reference and imidazole as pH
indicator for the NMR spectra. After preparation, samples were transferred to 5mm
NMR tubes (Sigma-Aldrich, St. Louis, MO).
2.2.B 1D 1H-NMR Spectroscopy
The 1D 1H-NMR technique was conducted on hamster plasma samples collected
at the terminal point of the study (Aim 1) on a 600 MHz Agilent instrument, operating
at 599.773MHz frequency and a temperature of 300 K. Prior work by Martin et al [99]
was used as a starting point for the protocol, but further optimization was conducted.
One-dimensional NMR spectra were acquired using the Carr-Purcell-Meiboom-Gill
(CPMG) spin-echo sequence [99] with presaturation to attenuate broad signals from
proteins and lipoproteins. Application of the named pulse sequence resulted in
spectra with signals only from the small metabolites, due to their longer transverse
relaxation time. These spectra were measured using a spin-echo loop time of 0.16 s
and a recycling time of 14 s. A total of 64 scans were collected using a spectral
width of 10 parts-per-million (ppm) and an acquisition time of 4 s.
The NMR data were processed using ACD/ Spec Manager 7.00 software
(Advanced Chemistry Development Inc., Toronto, Canada). The principal of the
NMR spectrophotometer is that when an external magnetic field is applied, the
magnetic moment of the nucleus aligns itself with the applied field to create different
energy levels. Transitions of atomic nuclei between these energy levels over a
period of time are recorded as free induction decay (FID) files.
Since these FID files are time domain signal files, it is very difficult to differentiate
between the spectra of different compounds. Therefore, the FID files are further
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stacked together as a group and then transformed by Fourier transformation (Ft,
mathematical algorithm) to a frequency domain. After Ft, the acquired spectrum can
be resolved into different peaks arising from different compounds or metabolites.
Each metabolite is represented by single or multiple peaks in the spectra and the
height of the peak represents the intensity/concentration of the metabolite. Spectra
were processed by editing, auto-phasing, and auto-baseline correction using the
ACD software. Intelligent binning was used to divide the edited spectra into 1000
bins. The spectra was further digitized to a table of common integrals and exported
as a non-negative value text file for multivariate data analysis.
2.2.C Multivariate Data Analysis (MVDA)
Once 1H-NMR spectra were converted to numeric values (digitized) using ACD
software, MVDA was used for pattern recognition in the data set. This analysis was
accomplished using SIMCA P+13.0 statistical software (Umetrics, Kinnelon, NJ).
PCA is a multivariate projection method designed to extract and display the
systemic variation in the data (the table of integrals from NMR plasma samples). This
unsupervised analysis was applied to the spectra of animals that received water,
complete PAZ, and the biologically active fraction, and any differences between the
metabolites were investigated. The corresponding loading plot provided information
about the parts of the spectrum that are responsible for the similarities and/or
dissimilarities in the data set. PLS is a regression extension of PCA and was used to
correlate the plasma metabolomic profile with other measured factors, such as HDL
cholesterol. In PLS-DA the data set was distributed into classes and its objective was
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to find a model that separates the classes of observation on the basis of their Xvariables, while using a hypothetical Y-variable.
2.2.D Metabolite Identification and Quantification
MVDA was used to determine the regions of the spectra responsible for
similarities and/or dissimilarities between the groups. Further, the focus was on the
peaks of spectrum that differentiate the groups, and the corresponding metabolites
within that range, which were identified using Chenomx NMR 7.6. Profiling of the
NMR spectra was accomplished using the Profiler module. Metabolites from the data
base were identified and quantified, and the pathways affected by the respective
metabolites were identified using online KEGG database.
2.3 AIM 3) To determine the therapeutic effect of the biologically active fraction
on hypercholesterolemia
Rationale: The aim was to determine the therapeutic effect of the biologically
active fraction on animals which had already achieved a hypercholesterolemic state.
Secondly, this part of the study aimed to determine the time course required for the
effect of the biologically active fraction on lipid parameters.
In order to achieve this aim, the animals were fed high fat diet for the first four
weeks of the study. This was followed by administration of the biologically active
fraction via their drinking fluid for 3, 7, 10, 14, and 21 days, respectively. All groups
were sacrificed following the same procedure as in Aim 1 for blood and tissue
collection. Further, mRNA was extracted from liver tissues to determine the changes
in the gene expression related to HDL cholesterol metabolism.
2.3.A Animal Protocol and Experimental Design
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Forty male Golden Syrian hamsters (Mesocricetus auratus), LVG strain were
purchased from Charles River Laboratories, Wilmington, MA. Upon arrival they were
8 weeks old and weighed approximately 80 g each. The animals were acclimatized
and given water and laboratory rodent diet 5001(Lab Diet, Richmond, IN) ad libitum
for one week prior to the initiation of the experimental treatment. They were housed
individually in a temperature-controlled room (25°C ) and maintained on a 12-h
light/dark cycle.
Animals were randomly distributed into 5 groups (n=8; T3, T7, T10, T14, and T21)
and fed HF diet for 4 weeks prior to the treatment regimen (Figure 2.3). The
biologically active fraction, (20% v/v) was administrated as their drinking fluid for 3
days (to T3 group), 7 days (to T7 group), 10 days (to T10 group), 14 days (T14
group), and 21 days (T21 group), respectively, as their treatment. HW group from Aim
1 was considered as T0 groups in this study and served as control, as the animals in
this group received HF diet for 4 weeks and water as their drinking fluid. At each end
point of the study, same procedure described in Aim 1A was used to sacrifice the
animals and collect blood and tissues.

53

Male Golden Syrian
Hamsters (n=40)

HF diet + Water for 4 weeks

T3 (n=8)
3 days on
BAF

T7 (n=8)
7 days on
BAF

Figure 2.3 Study Design for Aim 3

T10 (n=8)
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BAF

T14 (n=8)
14 days on
BAF

T21 (n=8)
21 days
on BAF
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2.3.B Plasma Lipid Analysis
Various lipid assays were performed on the collected plasma to determine the
changes in the lipoprotein concentrations as a result of the therapeutic intervention
with the biologically active fraction of PAZ. Plasma TC and TG concentrations were
determined enzymatically, while HDL cholesterol was measured enzymatically in the
supernatant following precipitation with Mg2+/dextran sulfate as previously described
(Pointe Scientific, Canton, MI). The concentration of non-HDL cholesterol was
calculated as the difference between the measured TC and HDL cholesterol, and
included the sum of VLDL, IDL, and LDL cholesterol.
Total Cholesterol Assay
As previously discussed under Aim 2.1.B
Triglyceride Assay
As previously discussed under Aim 2.1.B
HDL Cholesterol Assay
As previously discussed under Aim 2.1.B
2.3.C Real Time Polymerase Chain Reaction for Gene Expression Analysis
Total RNA Extraction
As previously discussed under Aim 2.1.C
Total RNA to cDNA Preparation
As previously discussed under Aim 2.1.C
Real time RT-PCR Analysis
As previously discussed under Aim 2.1.C (relative transcription levels of Apo A1)
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2.3.D Statistical Analysis
All data were expressed as the mean ± standard error (SE). Differences between the
control (HW/T0) and treatment groups (T3, T7, T10, T14, and T21) were determined
using one-way analysis of variance tests. The data were analyzed to determine the
therapeutic effect of the biologically active fraction of PAZ relative to distilled water,
after the animals were fed a high fat diet for 4 weeks. Statistical significance was
defined as P < 0.05.
2.4 AIM 4) To investigate the change in plasma metabolomic profiles upon
therapy with the biologically active fraction
Rationale: Plasma metabolomic profile using one-dimensional proton NMR was
performed to determine the changes in the concentration of metabolites present in
the control group (T0) and the treatment group representing the final time point, T21.
Data were analyzed using multivariate data analysis SIMCA P+ software. Targeted
profiling was applied to NMR spectra to determine the metabolites that have a
significantly different concentration between the groups. Once these metabolites
have been identified and quantified using CHENOMX software, analysis of the
pathways involving the specific metabolites was conducted.
2.4.A Sample Preparation
As previously discussed under Aim 2.2.A
2.4.B 1D 1H-NMR Spectroscopy
As previously discussed under Aim 2.2.B
2.4.C Multivariate Data Analysis
As previously discussed under Aim 2.2.C
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PCA and PLS-DA were applied to T0 and T21 groups to look for any differences
between the metabolites. PLS was used to correlate plasma lipid profile with the
metabolomic data.
2.4.D Metabolite Identification and Quantification
As previously discussed under Aim 2.2.D
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CHAPTER 3
RESULTS
3.1 AIM 1: To determine the biological activity of complete PAZ and its
subfractions in a hypercholesterolemic animal model
3.1.A Metabolic Effects of High Fat Diet and PAZ Supplementation
All hamsters survived the entire duration of the study. Animals in all experimental
groups consumed similar amounts of food (grams) and fluid (ml). The final body
weight and weight gained over the duration of the study was not significantly different
among high fat groups or the control; however CP had a significantly lower body
weight and weight gain as compared with the groups that received the high fat diet.
Liver weights were also not significantly different between groups (Table 3.1).
The change in body weight over time is shown in Figure 3.1. Week 0 represents
the body weight (grams) that the animals had upon arrival, whereas week 0’
represents the body weight after the first week of acclimatization, when animals were
fed regular diet. Week 0’ was the starting point on the high fat diet, and week 4 was
the final time point of the study. There was a similar trend in body weight gain for all
animals; however the animals receiving the high fat diet had a faster growth rate as
compared with the animals receiving regular purified diet.
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Table 3.1 Anthropometrics of Male Hamsters Fed High Fat Diet and PAZ or its
Fractions for 4 Weeks as a Potential Preventative Agent for Hypercholesterolemia
CW

CP

HP

HF1

HF2

HF3

HF4

106.9±2

104.9±3*

119 ±3

117±3

117±3

118±3

122±2

119±3

Body weight
21.6±1
gain, g/4 wk

19.7±2.5*

32.7± 2

29.7±2

30.3±2.6

33.1±3

29.9±3.1

31.1±1

Food Intake,
g/d

6.2±0.1

6.2±0.2

7.1±0.1

6.8±0.1

6.7±.0.2

6.8±0.2

7.0±0.2

6.6±0.2

Energy Intake,
Kcal/day

22.6±0.4

22.6±0.7

29.3±0.4

28.1±0.4

27.7±0.8

28.1±0.8

28.9±0.8

27.3±0.8

Fluid intake,
ml/d

8.8±0.4

8.7±0.5

8.3 ±0.2

8.2±0.6

8.3±0.7

7.7±0.5

7.7±0.4

7.2±2.1

Liver weight, g

3.8 ±0.1**

3.7 ±0.1**

5.4 ± 0.2

5.8±0.3

5.5±0.2

5.4±0.3

5.5±0.3

5.4±0.2

Body weight, g

HW

Notes: Values are mean ± SE, n = 10/group. * P < 0.05, CP vs. all treatment groups
(high fat diet); **P < 0.001, CW and CP vs. all treatment groups (high fat diet). Statistical
program ANOVA with Tukey’s procedure was used, SPSS software.
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Figure 3.1 Change in Body Weight over 4 Weeks of the Study. Male hamsters
received high fat diet and PAZ or one of the fractions for the duration of the study,
starting with week 0’. Values are mean of the body weight of all animals from the
group. N = 10/group
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3.1.B Plasma Lipid Analysis
In order to determine that the hypercholesterolemic state was induced in the
animals that received a high fat diet, plasma TC, TG, and non-HDL cholesterol
concentrations were measured in animals that received regular diet and water (CW)
and high fat diet and water (HW). Results showed a significant increase in plasma TC
and non-HDL cholesterol. The TG in HW group were also increased, but did not
reach significance (Figure 3.2). Therefore, we concluded that we successfully
induced a hypercholesterolemic state in the animal model.
When comparing the groups on high fat diet alone, plasma total cholesterol
(Figure 3.3) and triglycerides (Figure 3.4) were not significantly different in the
treatment groups as compared with the high fat controls, HW. However, the TC/HDL
cholesterol ratio was significantly lower in all experimental animals when compared
with controls (P < 0.05 in the HP, HP1, and HP2 groups; P < 0.001 in the HP3 and
HP4 groups, Figure 3.5). Consumption of PAZ or its fractions lowered non-HDL
cholesterol concentrations in the HP group (P < 0.05) and in the HP3 and HP4 (P <
0.001) groups, as compared with the controls (Figure 3.6). Moreover, the
concentration of plasma HDL cholesterol was significantly increased in the HP, HP3,
and HP4 groups (P < 0.001), when compared with controls (Figure 3.7).

61
7

*

CW
HW

6
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Figure 3.2 Effect of High Fat Diet on Lipid Profile
Notes: Lipid parameters (TG, TC, and non-HDL cholesterol) of CW and HW groups.
Values are mean ± SE. * P < 0.001 as compared with CW group.
Abbreviations: TG, triglycerides; TC, total cholesterol; HDL, high lipoprotein
concentration; CW, control diet + water group; HW, high fat diet +water group
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Figure 3.3 Effect of PAZ and its fractions on Total Cholesterol Concentration
Notes: Values of total cholesterol measured in groups that received high fat diet
along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ fraction 2
(HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks. Values are mean
± SE. No sig. difference as compared with HW group.
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Plasma Triglycerides Concentration
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HF3
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Figure 3.4 Effect of PAZ and its fractions on Triglycerides Concentration
Notes: Values of triglycerides measured in groups that received high fat diet along
with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ fraction 2 (HF2),
PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks. Values are mean ± SE.
No sig. difference as compared with HW group.
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Figure 3.5 Effect of PAZ and its fractions on TC/ HDL Ratio
Notes: The ratio of TC/HDL cholesterol was measured in groups that received high
fat diet along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ
fraction 2 (HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks. Values
are mean ± SE. * P < 0.05, ** P < 0.001 as compared with HW group.

65
4

*

Plasma non-HDL Cholesterol
Concentration
(mmol/L)

3.5

**

**

HF3

HF4

3
2.5
2
1.5
1
0.5
0
HW

HP

HF1
HF2
Experimental Group

Figure 3.6 Effect of PAZ and its fractions on non-HDL Cholesterol Concentration
Notes: Values of non-HDL cholesterol measured in groups that received high fat diet
along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ fraction 2
(HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks. Values are mean
± SE. *P < 0.05, ** P < 0.001 as compared with HW group.
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Figure 3.7 Effect of PAZ and its fractions on HDL Cholesterol Concentration
Notes: Values of plasma HDL cholesterol measured in groups that received high fat
diet along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ fraction 2
(HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks. Values are mean
± SE. * P < 0.05 as compared with HW group.
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Ultracentrifugation was performed on pooled plasma (4-5 hamsters/group) and
lipoprotein fractionation indicated that a higher proportion of cholesterol was carried
in the HDL fraction in the HP group (Figure 3.8), as compared with HW group.
Particle sizes for LDL (Figure 3.9) were calculated and there was no statistical
difference between the groups that received PAZ or its subfractions, when compared
with HW. However, when HDL particle size was measured, data showed that the
particle sizes of HF3 and HF4 groups were significantly increased as compared with
control group (Figure 3.10). Data augment the previous finding that HDL cholesterol
concentration has been increased in these groups, but also the particle size was
enlarged.
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Figure 3.8 Effect of PAZ on Lipoprotein Particle Distribution
Note: The graph depicts an increase in the high density particles in HP group (3.5
mmol/L) vs. HW (3.1 mmol/L) group. Total cholesterol concentrations were measured
in all fractions (0.5 mL/fraction) using standard enzymatic reagents. Graph represents
the mean of pooled plasma for HW and HP groups.
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Figure 3.9 Effect of PAZ and its fractions on LDL Particle Size
Notes: Values are mean ± SE. No sig. difference as compared with HW group. High
fat diet along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ
fraction 2 (HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4)
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Figure 3.10 Effect of PAZ and its fractions on HDL Particle Size
Notes: Values are mean ± SE. * P < 0.05 as compared with HW group. High fat diet
along with water (HW), complete PAZ (HP), PAZ fraction 1 (HF1), PAZ fraction 2
(HF2), PAZ fraction 3 (HF3), and PAZ fraction 4 (HF4) for 4 weeks
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3.1.C Effect of PAZ and its Subfractions on Gene Expression
In an attempt to elucidate the mechanism by which PAZ and its subfractions
altered the lipoprotein profile by increasing HDL, the activities of ABCA1, Apo A1,
SRB1, and CETP were assessed. When compared with the control group (HW),
hamsters fed the PAZ (HP group) and fraction 4 (HF4 group) had the highest fold
increase (approximately 5-fold) in Apo A1 expression, while the HP3 group showed
a minor increase (2-fold, Figure 3.11a). ABCA1 sterol transporter expression
showed a moderate increase in the HP3 and HP4 groups (1.7-fold and 1.8-fold,
respectively, Figure 3.11b), as compared with HW group.
In addition, SRB1 activity levels were also modestly higher in the HP3 and HP4
groups (approximately 2-fold, Figure 3.11c) when compared with controls. The
differences in the other treatment groups (HP1 and HP2) were not significant. The
data suggest that the increase in HDL cholesterol concentrations in the HP, HP3,
and HP4 groups was in part attributable to the increase in production of nascent
HDL cholesterol particles and/or clearance via SRB1 receptors. Hepatic CETP
expression was characterized by a 2-fold decrease only in the HP4 group as
compared with those receiving water alone (Figure 3.11d). Inhibition of CETP is
consistent with the decrease in plasma non-HDL lipoprotein along with the increase
in HDL cholesterol.
Correlations between plasma lipid concentrations and hepatic gene expression
levels were sought to identify potential relationships between molecular processes
and circulating lipid concentrations (Table 3.2). TC, non-HDL cholesterol, and
TC/HDL ratio were negatively correlated with hepatic expression of genes of ABCA1
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and SRB1. There was a significant positive correlation between plasma HDL
cholesterol concentrations and mRNA levels of Apo A1 (P < 0.01). In addition,
positive correlations between HDL cholesterol concentrations and mRNA levels of
SRB1 were observed.
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Figure 3.11 Effect of PAZ and its fractions on Gene Expression
Notes: Relative levels of expression of genes that encode key proteins involved in
the regulation of cholesterol and HDL metabolism in animals fed a high fat diet plus
complete PAZ (HP) or one of the fractions, as compared with the control group on
high fat diet and water (HW). Values are expressed as mean, n= 5 animals per
group (n=10 for HP group); Apo A1, Apolipoprotein A1 (3.11a); ABCA1, ATP-binding
cassette transporter A1 (3.11b); SRB1, Scavenger receptor class B member 1
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(3.11c); CETP, Cholesteryl ester transfer protein (3.11d). Each mRNA was
normalized with GAPDH and is expressed as a fold change.
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Table 3.2 Correlation between Plasma Cholesterol Concentrations and Expression
of Hepatic Genes
Genes

Total
cholesterol

APO A1
ABC A1
SRB 1
CETP

0.153
-0.068
-0.190
0.040

HDL
cholesterol
0.399*
0.252
0.252
-0.055

Note: Values are Pearson correlation, N = 10. *P < 0.01

TC/HDL
ratio
-0.342*
-0.33*
-0.420*
0.056

non-HDL
cholesterol
-0.243
-0.33*
-0.459*
0.099
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3.2 AIM 2: To investigate the change in plasma metabolomic profiles upon
administration of PAZ and the biologically active fraction
3.2.A Multivariate Data Analysis
To further investigate the preventative effect of the algal infusion PAZ on the
hypercholesterolemic hamsters, a metabolomic approach was applied to plasma
samples from control (HW) and treatment groups HP and HF4. One-dimensional
NMR spectra were acquired using the CPMG spin-echo sequence with
presaturation, in order to attenuate broad signals acquired from proteins and
lipoproteins. The resulting spectra have the signals from small metabolites only
(Figure 3.12). During the pre-processing of the spectra, the acquired NMR files were
edited, while auto-phasing and auto-baseline correction was applied (Figure 3.13).
The spectra were further digitized to a table of common integrals and exported as a
non-negative value text file for multivariate data analysis.
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Figure 3.12 NMR Spectrum obtained on 600 MHz Agilent Instrument, using CPMG
Spin-Echo Sequence with Presaturation
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Figure 3.13 1H NMR Spectra of HW, HP, and HF4 Groups
Notes: Spectra were stacked together as a group and transformed by Fourier
transformation to a frequency domain. Spectra were processed by editing, auto-phasing,
and auto-baseline correction. Further, intelligent binning was used to divide the edited
spectra in 1000 bins.
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To confirm that the metabolic profile of the hamsters that received high fat diet
was changed, PCA was performed on the NMR data. Three-dimensional PCA plot
(Figure 3.14) shows a clear separation between CW and HW groups, which
represents the effect of the high fat diet. PLS-DA of the same two groups, reinforcing
the effect of the diet is shown in Figure 3.15. We also analyzed CP and HP groups, to
look at the effect of diet and addition of PAZ, and a clear separation of the two groups
was observed (Figure 3.16).
Further, the focus was on the groups that received the high fat diet along with the
complete PAZ infusion or fraction 4 and compare them with the control group that
received water and high fat. Figure 3.17 represents the 3-dimensional PCA plot,
providing overall information on metabolic changes of the hamsters due to PAZ or
fraction 4 administrations, as compared with controls. To better analyze each
treatment group as compared with the control animals, PCA and PLS-DA was
conducted selecting two groups at the time.
The effect of complete PAZ infusion on the metabolic profile resulted in a clear
separation of the HP and HW groups, as shown in Figure 3.18. The effect of
administration of fraction 4 to the hamsters resulted in clustering of the HW and HF4
groups, showing an apparent separation based on their metabolic profiles (Figure
3.19a). The corresponding loading plot (Fig. 3.19b) provided significant information
on the contribution of each variable to the pattern in the score plots, which can aid in
metabolite identification in Chenomx software.
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Figure 3.14 Characterizations of the Plasma Metabolomic Changes Induced by High
Fat Diet. 3-Dimensional CMPG_PCA score plot revealed that CW and HW groups
were clearly separated. P < 0.05
Notes: CW, regular purified diet and water; HW, high fat diet and water. N = 8
hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PCA, principal components
analysis

Principal Component 2
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Principal Component 1
Figure 3.15 Characterizations of the Plasma Metabolomic Changes Induced by High
Fat Diet. 2-Dimensional CMPG_PLS-DA score plot revealed that CW and HW groups
were clearly separated due to the diet received. P < 0.05
Notes: CW, regular purified diet and water; HW, high fat diet and water. N = 8
hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PLS-DA, partial least squares –
discriminant analysis

Principal Component 2
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Principal Component 1
Figure 3.16 Characterizations of the Plasma Metabolomic Changes Induced by Diet
and PAZ Consumption. 2-Dimensional CMPG_PLS-DA score plot showing group
discrimination (CP vs. HP) based on PAZ and the diet received. P < 0.05
Notes: CP, regular purified diet and PAZ; HP, high fat diet and PAZ. N = 8
hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PLS-DA, partial least squares –
discriminant analysis
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Figure 3.17 Characterizations of the Plasma Metabolomic Changes Induced by High
Fat Diet and Drinking Fluid. 3-Dimensional CMPG_PCA score plot revealed that HW,
HP and HF4 groups were clearly separated. P < 0.05
Notes: HW, high fat and water; HP, high fat diet and PAZ; HF4, high fat and fraction
4. N = 8 hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PCA, principal components
analysis

Principal Component 2
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Principal Component 1

Figure 3.18 Characterizations of the Plasma Metabolomic Changes Induced by PAZ.
2-Dimensional CMPG_PLS-DA score plot showing group discrimination (HW vs. HP)
based on PAZ administration. P < 0.05
Notes: HW, high fat diet and water; HP, high fat diet and PAZ. N = 8 hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PLS-DA, partial least squaresdiscriminant analysis
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a

b

Figure 3.19 Characterizations of the Plasma Metabolomic Changes Induced by
Fraction 4. 3.19a. 3-Dimensional CMPG_PCA score plot revealed that HW and HF4
groups were clearly separated. P < 0.05; 3.19b CMPG_PCA corresponding loading
plot indicating the regions of the spectra that are responsible for the group separation
Notes: HW, high fat diet and water; HF4, high fat diet and fraction 4. N = 8
hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PCA, principal components
analysis
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Further, the discriminant analysis indicated that the treatment with PAZ and
fraction 4 induced specific metabolites patterns that enabled class assignment of the
hamsters (Figure 3.20). The PLS-DA score plot revealed that the group that received
PAZ was clearly separated by the principal component 1 from the group that received
fraction 4.
In addition, 2-dimensional PLS plot allowed for the evaluation of the PAZ and
fraction 4 on changes in the plasma metabolome, inducing a significant coefficient of
determination R² = 0.6, when the data were correlated with the plasma HDL
concentrations (Fig. 3.21). The PLS regression between the plasma HDL
concentration and the NMR variable revealed that 60 % of the variations in the
plasma profile can be predicted by different treatment conditions (PAZ vs. fraction 4).
Furthermore, PLS analysis showed that HDL cholesterol concentrations were
positively correlated with the plasma metabolic profile, indicating that the composition
shift toward the higher density lipoproteins is reflected in the change in
concentrations of some of the small metabolites present in plasma.

Principal Component 2
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Principal Component 1
Figure 3.20 Characterizations of the Plasma Metabolomic Changes Induced by PAZ
and F4. 2-Dimensional CMPG_PLS-DA score plot showing group discrimination (HF4
vs. HP) based on PAZ and F4 administration. P < 0.05
Notes: HF4, high fat diet and fraction 4; HP, high fat diet and PAZ. N = 8
hamsters/group.
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; PLS-DA, partial least squares –
discriminant analysis

Y= Plasma [HDL]
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X= Metabolomic profile
Figure 3.21 Correlation of the PAZ fraction- induced plasma metabolomic and HDL
cholesterol.
Notes: Changes among the metabolomic score values (X) of individual hamsters fed
a high fat diet and different drinking fluids (F4 or PAZ fraction) are plotted along with
the corresponding individual plasma HDL scores (Y), as determined by the PLS
analysis. The coefficient of determination (R² = 0.6) among X and Y that was
calculated after linearization of the relationship is indicated.
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3.2.B Metabolite Identification and Quantification (Chenomx)
A total of fifty plasma metabolites of the control and treatment groups were
identified and quantified using Chenomx NMR Suite software, including amino acids
(leucine/isoleucine, valine), organic acids (3-hydroxybutyrate, lactate, acetate,
acetoacetate, citrate, pyruvate, creatine, creatinine), carbohydrates (glucose,
galactitol, glucitol), and phospholipids-associated molecules. The metabolites that
had a significantly lower concentration in the group that received the algal infusion
PAZ and in the group that received fraction 4 are summarized in Table 3.4 and 3.5,
respectively.
Results indicated that the concentrations of betaine, phosphocholine, and
glycerol-phosphocholine were significantly lowered in HP group as compared with
HW. Treatment with the algal infusion PAZ on hypercholesterolemic hamsters also
resulted in decreased levels of several amino acids, such as arginine, leucine,
isoleucine, threonine, taurine.
When the experimental animals received the fraction 4 of PAZ (HF4 group), the
concentration of additional metabolites resulted to be significantly lower, as compared
with the control group. Besides the metabolites that were found to be significantly
lower in HP group, we determined that sixteen additional metabolites were decreased
in the group that received fraction 4 (HF4) as a preventative agent. Additionally to the
phospholipids-associated

metabolites

betaine,

phosphocholine,

and

glycerol-

phosphocholine, which recently have been linked to atherosclerosis, we also found
that also choline, carnitine, and trimethylamine N-oxide (TMAO) have been
significantly reduced in HF4 group.
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Table 3.3 Metabolites with Significantly Lower Concentration in Hypercholesterolemic
Hamsters that Received PAZ for 4 Weeks as a Preventative Agent as Compared with
HW

Metabolites

Peak Regions (ppm)

Acetoacetate

2.3, 3.4

Arginine

1.6, 1.7, 1.9, 3.2, 3.8

Betaine

3.3, 3.9

Glucitol

3.6, 3.7, 3.8

Glutamine

2.1, 2.4, 3.8, 6.9, 7.6

Glycerol

3.6, 3.8

Isoleucine

0.9, 1.0, 1.2, 1.5, 2.0, 3.7

Leucine

0.9, 1.7, 3.7

Glycero-phosphocholine

3.2, 3.6, 3.7, 3.9, 4.3

Taurine

3.2, 3.4

Threonine

1.3, 3.6, 4.3
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Table 3.4 Metabolites with Significantly Lower Concentration in Hypercholesterolemic
Hamsters that Received F4 as a Preventative Agent as Compared with HW

Metabolites
2-Aminobutyrate
3-Hydroxybutyrate
Acetate
Acetoacetate
Alloisoleucine
Arabinitol
Arginine
Betaine
Carnitine
Choline
Galactitol
Glucitol
Glucose
Glutamine
Glycerol
Isoleucine
Lactate
Leucine
Malonate
O-Phosphocholine
Pyruvate
Glycero-phosphocholine
Succinate
Taurine
Threonine
Trimethylamine N-oxide
Valine

Peak Regions (ppm)
1.0, 1.9, 3.7
1.2, 2.3, 2.4, 4.1
1.9
2.3, 3.4
0.9, 1.0, 1.3, 1.4, 2.1, 3.7
3.6, 3.7, 3.8, 3.9
1.6, 1.7, 1.9, 3.2, 3.8
3.3, 3.9
2.4, 3.2, 3.4, 4.6
3.2, 3.5, 4.1
3.7, 4.0
3.6, 3.7, 3.8
3.2, 3.4, 3.5, 3.7, 3.8, 3.9, 4.7, 5.2
2.1, 2.4, 3.8, 6.9, 7.6
3.6, 3.8
0.9, 1.0, 1.2, 1.5, 2.0, 3.7
1.3, 4.1
0.9, 1.7, 3.7
3.1
3.2, 3.6, 4.1
2.4
3.2, 3.6, 3.7, 3.9, 4.3
2.4
3.2, 3.4
1.3, 3.6, 4.3
3.2
1.0, 2.3, 3.6
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3.3 AIM 3: To determine the therapeutic effect of the biologically active fraction
on hypercholesterolemia
3.3.A Metabolic Effects of High Fat Diet and Treatment with Fraction 4
Animals were fed a high fat diet and water for the first four weeks of the study,
time that represented the end point for T0. After four weeks, groups T3, T7, T10,
T14, and T21 received the biologically active fraction of PAZ as their drinking fluid
for 3, 7, 10, 14, and 21 days, respectively, while continuing the high fat diet. Animals
were sacrificed at different time points, based on the number of days they were
designed to receive treatment.
The net body weight gain of the animals for the first 4 weeks of the study, as well
as the food efficiency ratio (g gained/ g feed) were statistically significant in group T7
(P < 0.05, Table 3.5). The ratio of fluid/water intake and the ratio of liver weight/body
weight were not statistically different when compared with T0 group (Table 3.5).
While on treatment with PAZ fraction, all animals survived the duration of the study
and no abnormal characteristics related to the physiology of the animals were noted.
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Table 3.5 Anthropometrics of Male Hamsters Fed High Fat Diet and Water for 4
Weeks, Followed by High Fat and F4 Treatment for 0, 3, 7, 10, 14, and 21 Days
T0

T7

T3

T10

T14

T21

Body
weight
gain, g/4
weeks

37.2±2.1

40.8±3.7

50.6±6.2*

44.2±3

34.4±3.5

39.8±2.9

Food
intake, g/d

7.1±0.1

7.4±0.2

7.5±0.2

7.4±0.2

6.9±0.2

7.4±0.1

0.22±0.01*

0.2±0.01

0.17±0.01

0.19±0.01

Food
efficiency
ratio, g
gain/g
feed
Fluid
intake,
PAZ/water
Liver/body
weight

0.16±0.01 0.2±0.02

1.0±0.0

0.96±.04

0.95±.05

1.1±.04

1.0±.06

1.1±.04

4.6 ±0.1

4.9±0.1

4.7±0.1

4.8±0.1

4.7±0.1

4.5±0.2

Notes: Values are mean ± SE, N = 10/group (T0), N = 8/group (T3, T7, T10, T14,
T21). *P < 0.05 when compared with T0. Statistical program ANOVA with Tukey’s
procedure was used, SPSS software
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3.3.B Plasma Lipid Profile upon Therapy with Fraction 4
Plasma lipid profile of the hypercholesterolemic hamsters was enzymatically
measured to determine the therapeutic effect of fraction 4 when administrated as the
drinking fluid. Plasma TC (Figure 3.22) and TG (Figure 3.23) were not significantly
reduced in the treatment groups while receiving the fraction 4, as compared with the
control group. However, the TC/HDL ratio was significantly lower in all treatment
groups when compared with the control T0 group (P < 0.001, Figure 3.24). Moreover,
the concentration of HDL cholesterol was significantly increased in T3 group (P <
0.05), as well as in group T21 (P < 0.001), when compared with the control group
(Figure 3.25).
Consumption of the biologically active fraction of PAZ, F4 also significantly
reduced the non-HDL cholesterol in all groups, as compared with the control animals
(P < 0.001 in T3, T7, and T10; P < 0.05 in T14 and T2, Figure 3.26). These results
corroborates with our previous findings that ingestion of PAZ and its biologically
active fraction can improve the plasma lipoprotein profile by significantly increasing
the HDL cholesterol concentrations, while decreasing the non-HDL cholesterol and
TC/HDL ratio in hypercholesterolemic hamsters.
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Figure 3.22 Effect of Fraction 4 on Total Cholesterol Concentration
Notes: Plasma total cholesterol concentrations in male hamsters fed high fat diet for
4 weeks, followed by high fat and F4 for 0, 3, 7, 10, 14, and 21 days. Values are
mean ± SE. No sig. difference as compared with T0 group.
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Figure 3.23 Effect of Fraction 4 on Triglycerides Concentration
Notes: Plasma triglyceride concentrations in male hamsters fed high fat diet for 4
weeks, followed by high fat and F4 for 0, 3, 7, 10, 14, and 21 days. Values are mean
± SE. No sig. difference as compared with T0 group.
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Figure 3.24 Effect of Fraction 4 on TC/HDL Cholesterol Concentration
Notes: Plasma TC/HDL cholesterol concentrations in male hamsters fed high fat diet
for 4 weeks, followed by high fat and algal treatment for 0, 3, 7, 10, 14, and 21 days.
Values are mean ± SE. *P < 0.001 as compared with T0 group.

98

Plasma HDL Cholesterol Concentration
(mmol/L)

4.5

*

4

**

3.5
3
2.5
2
1.5
1
0.5
0
T0

T3

T7
Experimental Group

T10

T14

T21

Figure 3.25 Effect of Fraction 4 on HDL Cholesterol Concentration
Notes: Plasma HDL cholesterol concentrations in male hamsters fed high fat diet for
4 weeks, followed by high fat and algal treatment for 0, 3, 7, 10, 14, and 21 days.
Values are mean ± SE. *P < 0.05, **P < 0.001 as compared with T0 group.
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Figure 3.26 Effect of Fraction 4 on non-HDL Cholesterol Concentration
Notes: Plasma non-HDL cholesterol concentrations in male hamsters fed high fat
diet for 4 weeks, followed by high fat and algal treatment for 0, 3, 7, 10, 14, and 21
days. Values are mean ± SE. *P < 0.01, **P < 0.001 as compared with T0 group.
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3.3.C Therapeutic Effect of the Biologically Active Fraction (F4) on Apo A1
Gene Expression
In order to determine the therapeutic potential of the biologically active fraction of
PAZ at the molecular level and to validate the significant increase in HDL cholesterol
concentration, the activity of Apo A1 gene expression was evaluated. Also, the
earliest time point at which the genetic expression is altered was determined. Apo
A1 gene expression analysis showed that hamsters fed the biologically active
fraction for 10 days (T10) had a moderate (3-fold) increase, while hamsters fed the
PAZ fraction for 21 days exhibit an approximate 6-fold increase (Figure 3.27).
These results correlate with the increase in the plasma concentration of HDL
cholesterol, as Apo A1 is responsible for the production of nascent HDL cholesterol
particles. Thus the active fraction of PAZ increased HDL concentration at least in
part by increased production of nascent HDL particles both when given as a
treatment or preventative agent [100].
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Figure 3.27 Relative Levels of Hepatic mRNA Expression of Apo A1 Gene in
Hypercholesterolemic Hamsters.
Notes: Animals were fed a high fat diet for 4 weeks, followed by high fat diet plus F4
for 0, 3, 7, 10, 14, and 21 days, respectively. Values are expressed as mean of
threshold cycle (ct) values; n=8 animals per group (n=5 for T0 group). Each mRNA
was normalized with GAPDH and is expressed as a fold change.
Abbreviations: ApoA1, Apolipoprotein A1
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3.4 Aim 4: To investigate the change in plasma metabolomic profiles upon
therapy with the biologically active fraction F4
3.4.A Multivariate Data Analysis
To investigate the therapeutic effect of the biologically active fraction on the
hypercholesterolemic hamsters, a metabolomic approach was applied to plasma
samples from controls (T0) and 21 days treatment group (T21) by

1

H NMR

spectroscopy. PCA was performed on the NMR data to get the overall information
on metabolomic profile of hamsters, due to fraction 4 administration. The clustering
of the T0 and T21 groups showed a clear separation of the hamsters in PCA plots
(Figure 3.28a). Due to the fact that one of the samples in group T21 was outside of
the ellipse of Hotelling’s 95% confidence interval, it was considered a strong outlier
and removed from the PCA analysis. The corresponding loading plot (Figure 3.28b)
along with the variable importance on projection (VIP) plot (Figure 3.28c) provided
significant information on the contribution of each variable to the pattern in the score
plots, which can aid in metabolite identification in Chenomx software.
The discriminant analysis (PLS-DA) indicated that the treatment with PAZ
fraction for 21 days induced specific metabolites patterns that enabled class
assignment of the hamsters (PLS-DA, Figure 3.29). The PLS-DA score plot revealed
that the control and treatment group were clearly separated by the principal
component 1. In addition, the 2- dimensional PLS plot (Figure 3.30 a, b) allowed for
the evaluation of the F4 treatment on changes in the plasma metabolome. For
instance, the treatment with the active fraction for 21 days induced a significant
coefficient of determination R² = 0.7, when the data were correlated with the plasma
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lipid profile (Figure 3.30a). The PLS regression between the NMR variables and the
plasma lipid profile revealed that 70% of the variations in the lipid profile can be
predicted by different treatment conditions (water vs. F4).
Furthermore, as determined by the PLS analysis, HDL cholesterol concentrations
were positively correlated with the plasma metabolomic profile (R² = 0.62), indicating
that there is a positive correlation between the higher density lipoproteins
concentrations and some of the small metabolites present in plasma (Figure 3.30b).
Moreover, the orthogonal projections to latent structures (OPLS) aides in the
process of identifying statistically significant and potentially biochemical significant
metabolites based on contribution to the model and their reliability. The OPLS_S
Plot (Figure 3.31) provided important information on the contribution of each variable
to the pattern in the score plots, specifically was used to identify possible
metabolites that correlate the metabolomic profile to HDL cholesterol concentration.
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Principal Component 2

a

Principal Component 1
b

Figure 3.28 Characterizationss of the Plasma Metabolomic
bolomic Changes Induced by F4
3.28a.. CMPG_PCA score plot revealed that T0 and T21 groups were clearly separated
along [t1] and [t2]. P < 0.05; 3.28
3.28b.. CMPG_PCA corresponding loading plot indicating
the regions of the spectra that are responsible for the group separatio
separation
Notes: T0, high fat diet and water; T21
T21, high fat diet and F4 for 21 days.
N = 8/hamsters per group.
Abbreviations: CPMG, Carr--Purcell-Meiboom-Gill;
Gill; PCA, principal components analysis;
PLS-DA,
DA, partial least squares
squares-discriminant analysis
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Figure 3.28c. Characterizations of Plasma Metabolomic Changes Induced by F4.
Notes: Variable importance on projection (VIP) plot shows the contribution of each
variable to the pattern, with the regions of spectra in the far most left of the plot carrying
most of the weight.

Principal Component 2

106

Principal Component 1

Figure 3.29 Characterizations of the Plasma Metabolomic Changes Induced by F4.
Two-dimensional PLS-DA score plot showing group discrimination based on treatment
received. P < 0.05
Notes: T0, high fat diet and water; T21, high fat diet and F4 for 21 days. N = 8 hamsters
per group.
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Y= Lipid profile

Y= Plasma HDL

b

X = Metabolomic profile

X = Metabolomic profile

Figure 3.30 Correlation of the Fraction 4-Induced Plasma Metabolomic and Lipid
Profile.
Notes: Changes among the metabolomic score values (X) of individual hamsters fed a
high fat diet and different drinking fluids (water or F4) are plotted along with the
corresponding individual plasma lipid profile scores (Y), as determined by the PLS
analysis. The coefficient of determination (R²) among X and Y that was calculated after
linearization of the relationship is indicated; 3.30a Relationship between the plasma
metabolomic and complete lipid profile. (R² = 0.7); 3.30b Relationship between the
plasma metabolomic profile and HDL cholesterol. (R² = 0.62); N = 8 hamsters per
group.
Abbreviations: T0, high fat diet and water; T21, high fat diet and fraction 4 for 21 days.
PLS, partial least squares
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Figure 3.31 Characterizations of the Plasma Metabolomic Changes Induced by F4.
Notes: CPMG_OPLS-S plot used to identify possible metabolites that correlate the
metabolomic profile to HDL cholesterol metabolism
Abbreviations: OPLS, orthogonal partial least square
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3.4.B Metabolite Identification and Quantification (Chenomx)
A total of fifty plasma metabolites of the control and treatment groups were
identified and quantified using Chenomx NMR Suite software, including amino acids
(leucine/isoleucine, valine), organic acids (3-hydroxybutyrate, lactate, acetate,
acetoacetate, citrate, pyruvate, creatine, creatinine), carbohydrates (glucose,
galactitol, glucitol), phospholipids-associated molecules. The metabolites that had a
significantly lower concentration in the group that received the biologically active
fraction for 21 days are summarized in Table 3.6.
Results indicated that the concentrations of choline, phosphocholine, glycerolphosphocholine, betaine, and carnitine, were significantly lowered in T21 group as
compared with T0. Treatment with the biologically active fraction of PAZ on
hypercholesterolemic hamsters also resulted in decreased levels of several amino
acids (arginine, leucine, isoleucine, threonine, taurine), as well as some other
important molecules (3-hydroxy-butyrate, acetate, glycerol) involved in fatty acids
metabolism.
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Table 3.6 List of Plasma Metabolites Quantified to be at Lower Concentrations
After 21 Days of Treatment
Metabolites

Peak regions (ppm)

Metabolites

Peak regions (ppm)

2-Aminobutyrate

1.0, 1.9, 3.7

Glucitol

3.6,3.7,3.8

3-Hydroxybutyrate

1.2, 2.3,2.4,4.1

Glycerol

3.6,3.8

Acetate

1.9

Isoleucine

0.9,1.0,1.2,1.5,2.0,3.7

Arabinitol

3.6,3.7,3.8,3.9

Lactate

1.3,4.1

Arginine

1.6,1.7,1.9,3.2,3.8

Leucine

0.9,1.7,3.7

Betaine

3.3,3.9

Phosphocholine

3.2,3.6,4.1

Carnitine

2.4,3.2,3.4,4.6

3.2,3.6,3.7,3.9,4.3

Choline

3.2,3.5,4.1

Glycerophosphocholine
Taurine

Galactitol

3.7,4.0

Threonine

1.3,3.6,4.3

3.2,3.4

Notes: Plasma metabolites found to be significantly lower in T21 group as compared
with T0 group. The metabolites were quantified using the Chenomx 7.6 NMR Suite
database and significance was obtained using 2 tailed Student t-tests, P < 0.05.
T0, high fat diet and water; T21, high fat diet and F4 for 21 days, N = 4
hamsters/group for quantification of metabolites.
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CHAPTER 4
DISCUSSION
The current study was designed to examine the preventative and therapeutic
effect of the algal infusion product Proalgazyme and its subfractions in a dietinduced hypercholesterolemic hamster model. More specifically, the objective was to
investigate the possible mechanism of action whereby certain fractions of PAZ can
influence the cholesterol metabolism pathway. In addition, the scope was also to
determine the plasma metabolomic profile and compare the changes produced with
the plasma lipid profile, and possibly identify new relationship between smaller
metabolites and hypercholesterolemia.
A hamster model was used in this study given that it is the most appropriate
model to study lipoprotein metabolism. Due to interspecies differences in the
lipoprotein metabolism, it is important to study the metabolic changes in a nonprimate model that develops the most similarities to the human disease. The
hamster model used in the current study has been previously found to be suitable for
exploring hypercholesterolemia associated with dietary changes [97] and the high fat
diet used was proven to induce a hypercholesterolemic state in the hamster model
[100]. As previously mentioned, plasma lipoprotein metabolism in hamsters is
comparable to humans due to similar component and metabolism of both
lipoproteins and bile acids [101, 102].
Different types of algal cellular biomass and algal extracts have been studied for
their ability to lower circulating cholesterol concentrations in hamsters consuming
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hypercholesterolemic diets [103] and in humans [104], and showed a reduction in
plasma total cholesterol, non-HDL cholesterol , and/or triglycerides concentrations.
Previous findings [68] when PAZ was administrated to humans for 10 weeks to
evaluate its effect on cardiovascular risk factors associated with the metabolic
syndrome, showed a decrease in plasma total cholesterol, non-HDL cholesterol, and
triglycerides concentrations. Moreover, the levels of HDL cholesterol were
significantly increased, and PAZ was well tolerated with no notable adverse effects
[68]. However, the large difference in the lipid profile of treatment versus the control
group needed more validation. The mechanism of action required further
investigation as well. Therefore, one of the objectives of the current study was to
determine the hypolipidemic effects of PAZ and its subfractions. Moreover, the
research investigated the mechanism by which plasma HDL cholesterol was
augmented and if the increase can be detected in the hepatic mRNA expression of
the key genes involved in HDL/RCT metabolism. Further, the plasma metabolomic
profile was analyzed and correlated with the lipid profile of the hypercholesterolemic
hamsters.
The results of the current study corroborate previous findings on plasma
lipoprotein concentrations upon administration of dietary PAZ [68]. Administration of
PAZ

and

its

subfractions

for

4

weeks

as

a

preventative

agent

for

hypercholesterolemia resulted in a significant improvement in plasma lipid profile
and an alteration in the genes involved in HDL/ RCT metabolism. Results showed a
highly significant reduction in non-HDL cholesterol and TC/HDL ratio in animals that
received fraction 3 (HF3 group) and 4(HF4 group), and a moderate decrease in
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groups HP (non HDL and TC/HDL), HF1 and HF2 (TC/HDL). In addition, the HDL
cholesterol concentration was significantly increased in HP, HF3, and HF4 groups.
To confirm the increase in HDL cholesterol plasma concentrations in the treatment
groups, plasma ultracentrifugation was performed on pooled plasma of all hamsters.
An increase in the high density portion of cholesterol was observed after TC assay
was performed on all fractions, confirming the raise in HDL cholesterol plasma
concentrations.
An important objective of the study was to explain the improvement in plasma
lipid profile upon administration of complete PAZ and its subfractions to hamsters
fed a high fat diet. Evaluation was performed on the genes involved in HDL
metabolism (Apo A1, ABCA1, SRB1, and CETP) in liver tissues collected from
hamster. Apo A1 is involved in the production of nascent HDL particles, while
ABAC1 transports lipids from peripheral tissues to nascent HDL to form larger HDL
particles. The mature HDL particle is removed via SRB1 receptor on the liver into
bile, clearance from plasma occurs, and Apo A1 molecule is recycled. CETP
transfers lipids from HDL to non-HDL particles, and partial inhibition of this enzyme
is beneficial for lowering cholesterol concentrations in plasma. Using a real time RTPCR technique, we have examined the ability of ProAlgaZyme to transcriptionally
regulate these genes involved in HDL/RCT metabolism in hepatic tissue.
Administration of PAZ and its subfraction 4 did alter the ABCA1, APO A1, SRB1
and CETP hepatic mRNA levels, regulating the transcription of genes that encode
specific proteins that control cholesterol levels. Transcription of Apo A1, ABCA1,
SRB1 genes was up-regulated, whereas transcription of the gene encoding CETP
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was down-regulated after 4 weeks dietary intervention with PAZ and/or its
subfraction 4. Therefore, high non-HDL cholesterol and TC concentrations, and low
HDL cholesterol can be treated by up-regulating ABCA1, APO A1, and SRB1, and
down-regulating CETP expression.
In summary, the real-time RT-PCR analysis of gene regulation using mRNA from
hamster liver samples corroborates the changes in lipid plasma profile noted in the
first part of the study. Therefore, we concluded that the biologically active fraction of
PAZ is fraction 4, and it was used to complete further aims in the project. The
composition of fraction 4 is, however uncertain at this point. One-dimensional 1H
NMR spectroscopy of the sample resulted in a spectrum with major peaks found
around 1.2- 2.0 ppm, as well as around 7.3 ppm. Current literature describes most
common classes of secondary metabolites in red and green algae as phytosterols,
phenylpropanoids and various phenolic compounds [105, 106]. Since the 1H NMR
spectra also showed prominent peaks in the aromatic regains as well as in the
region associated with alcohol groups, presence of phenols or phytosterols is
possible.
Further, the metabolomic plasma profile of hypercholesterolemic hamsters
treated with PAZ and fraction 4 was analyzed, using 1H NMR spectroscopy and
multivariate data analysis. Previous studies identified metabolic perturbations
associated with abnormal lipoprotein profile, kidney disease associated with type I
diabetics, insulin resistance, and atherosclerosis using NMR spectroscopy, this
being a method widely used in the last decade [83, 88].
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Plasma includes both high molecular weight proteins and lipoproteins, as well as
low molecular weight metabolites. Hence, the standard plasma 1-dimentional 1H
NMR spectrum is dominated by broad resonance peaks of the high molecular weight
components. The CPMG echo pulse technique was used to suppress the resonance
from the macromolecules and emphasize the low molecular weight metabolites, thus
revealing subtle biochemical information of the plasma samples. A clear separation
of the groups was obtained with the PCA and PLS-DA score plots, showing changes
in plasma profiles due to the PAZ intervention treatment. To identify the metabolites
responsible for this strong separation of the groups, PCA loading plot was analyzed
to identify the unique regions in the spectra that generate this separation. In addition,
Chenomx NMR Suite software along with the loading, VIP and S plot assisted in
identification and qualification of the low molecular weight metabolites present.
It is now well established that a high fat diet is highly correlated with an
atherogenic outcome. Independent from the effect of a high fat diet on lipid profile, a
number of recent metabolomic studies have identified abnormalities in branched
chain amino acids [107], choline, betaine, and TMAO metabolism [108-110] as being
highly increased in subjects with stable atherosclerosis, heart failure, and other
cardiovascular diseases. After screening more than 2000 metabolites from a large
cohort study (n= 1,876), Wang et al [110] found that a unique cluster of three
phospholipid-associated molecules, more specifically choline, betaine, and the final
metabolite, TMAO are linked to CVD risk. It has been shown by Wang et al [110]
that increased levels of these metabolites promoted up-regulation of several
macrophage scavenger receptors that correlated with atherosclerosis, making these
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phospholipid metabolites independent predictors for the risk of a clinical vascular
event. Even though the key culprits in atherosclerosis remain cholesterol and
triglycerides, the new findings had shifted the attention of scientists towards
phosphatidylcholine biosynthesis pathway for additional information related to risk
for CVD. Plasma levels of choline and betaine are dependent on the
proatherosclerotic phospholipid-rich diet, and are considered a key risk factor, rather
than a direct marker of CVD [111]. After quantification of these metabolites in our
plasma samples, we determined that the group that received the high fat diet and
the PAZ and/or fractions 4 had significantly lower levels of betaine, choline,
phosphocholine, glycerol-phosphocholine, as compared with the animals that
received the high fat diet and water. In addition, the group that received fraction 4
had a significantly lower concentration of TMAO, demonstrating that the biologically
active fraction provides enhanced benefits to the hypercholesterolemic animals.
TMAO was demonstrated to promote accelerated atherosclerosis and has been
proposed that TMAO induces up-regulation of macrophage scavenger receptors and
can contribute to augment the “forward cholesterol transport” [112].
Another recently studied metabolite that contains a trimethylamine structure
similar to that of choline is L- carnitine. Its fundamental role is to transport fatty acids
into the mitochondrial compartment [112], and it has been associated with potential
health risk related to CVD [113]. It has been shown that TMAO, and its precursors
choline and carnitine suppress in vivo reverse cholesterol transport, and elevated
levels of plasma carnitine in humans are significantly associated with risk for
coronary artery disease, peripheral artery disease, and overall CVD [114]. Our
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metabolomics analysis showed a significantly lower plasma concentration of
carnitine in the group that received fraction 4 as compared with the group that
received a high fat diet and water. This finding is of extreme importance, as it
appends to the increase in plasma HDL cholesterol, along with the decrease in nonHDL and TC/HDL ratio, all considered contributory factors towards prevention of
heart disease.
Furthermore, Aim 3 was designed to examine the therapeutic effect of fraction 4
in a diet-induced hypercholesterolemic hamster model. More specifically, the
objective of this study was to determine the efficacy of fraction 4 on plasma lipid and
metabolomic profile of animals that have been previously induced to a
hypercholesterolemic state. Also, the aim was to determine the earliest time point at
which the plasma profile was modified after treatment with fraction 4. Also, this is the
first study examining the plasma metabolomic profile of hypercholesterolemic
hamsters treated with fraction 4; therefore it is very important to determine the
changes in the concentration of small molecular weight metabolites due to fraction 4
therapeutics and how they correlate with the results from the preventative study.
The results of this therapeutic investigation reveal an improvement in the plasma
lipoprotein profile upon administration of fraction 4, showing a significant reduction in
non-HDL cholesterol and total cholesterol/HDL ratio in all treatment groups, as well
as a significant increase in plasma HDL cholesterol concentration. In addition, there
was a moderate (T7, T10, and T14 groups) and a highly significant increase (T21
group) in the hepatic mRNA levels of Apo A1 gene, which is involved in the
production of nascent HDL particles. Further, we analyzed the metabolic plasma
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profile of hypercholesterolemic hamsters treated with the biologically active fraction
of PAZ, using

1

H NMR spectroscopy and multivariate data analysis. A clear

separation of the groups was obtained with the PCA and PLS-DA score plots,
showing changes in blood plasma profiles due to therapy with fraction 4. To identify
the metabolites responsible for this strong separation of the groups, PCA loading
plot was analyzed to identify the unique regions in the spectra that generate this
separation. Chenomx NMR Suite software along with the PCA loading, VIP and S
plots assisted in identification and qualification of important low molecular weight
metabolites. After quantification of these metabolites in our plasma samples, it was
noticed that the group that received the high fat diet and fraction 4 for 21 days had
significantly lower levels of betaine, choline, phosphocholine, and glycerolphosphocholine, as compared with the animals that received the high fat diet and
water. Furthermore, our metabolomics approach showed a significant lower plasma
concentration of carnitine in the group that received BAF for 21 days as compared
with the group that received a high fat diet and water.
The concentration of these metabolites was also altered when PAZ and fraction 4
were administrated as a preventative agent in hypercholesterolemic hamsters,
therefore we can suggest that the phosphocholine-containing molecules and their
pathways are being altered by administration of PAZ and/or BAF. Figure 4.1
presents an overview of these pathways and the relationship between these
molecules and lipid metabolism.
Several researchers investigated the phosphocholine-containing molecules and
TMAO production and revealed that these molecules are gut-flora-dependent and
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several pathogens are responsible for the production of TMAO [110, 114, 115].
Previous

studies have also shown that the intestinal microbial community can

influence the efficacy of utilizing energy from the diet, and ultimately increase the
susceptibility to obesity [116]. More metabolomics studies have demonstrated the
active role of gut microbiota with the development of complex metabolic aberrations,
such as insulin resistance and non-alcoholic fatty liver disease [117].
Using a targeted metabolomics approach, Wang at el [110] and Koeth at el [114]
identified a novel pathway connecting dietary lipid intake, intestinal microflora and
atherosclerosis (Figure 4.2). This pathway represents a distinctive additional
contribution to the pathogenesis of atherosclerosis, demonstrating that gut mirobiota
engages in the metabolism of phospholipids to yield a molecule (trimethylamine),
which is further metabolized to TMAO in the host and ultimately contribute to
formation of atherosclerosis. Thus, the current findings are of extreme importance,
demonstrating that PAZ and its BAF can alter not only the concentration of important
phosphocholine-containing molecules, but may also change the gut microbiota
leading to altered production of TMAO.
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Figure 4.1 Diagram of the Glycerolphosphate Pathway and Phosphatidylcholine
Synthesis [118]

121

Figure 4.2 Gut-flora Dependent Metabolism of Phosphocholine and Atherosclerosis.
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CONCLUSION
The present study has shown that dietary administration of PAZ and/or its
biologically active fraction can improve the plasma lipoprotein profile, hepatic mRNA
expression of genes involved in HDL/ RCT mechanism, as well as the concentration
of low molecular weight metabolites in plasma. These modifications were achieved
when fraction 4 of PAZ was administrated both as a preventative and as a
therapeutic

agent,

suggesting

the

potential

benefit

of

this

agent

in

hypercholesterolemia.
The data suggest that administration of PAZ and the biologically active fraction
results in a favorable lipoprotein profile in hamsters, primarily due to the effects on
multiple targets in the reverse cholesterol transport pathway. In addition to improving
the well known risk factors associated with CVD, the potentially valuable effect of the
algal infusion on relatively new predictors of atherosclerosis, such as branched chain
amino acids and the phosphocholine- containing molecules was identified.
It was also shown that the biologically active fraction can alter the pathway
linking the phospholipids, intestinal microflora and atherosclerosis. The proatherogenic gut-flora-generated metabolite TMAO was significantly reduced when
fraction 4 was administrated along with high fat diet as a preventative agent to
hypercholesterolemic hamsters.
This study therefore further supports the dietary use of PAZ and/or its biologically
active fraction for the prevention and management of dyslipidemia-related diseases
such as cardiovascular disease and metabolic syndrome. Also, this research
illustrates how the metabolomics approach can drive biomarker discovery and
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generate new hypothesis for new treatments, opening exciting avenues for future
research.
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ABSTRACT
THE EFFECT OF PROALGAZYME AND ITS SUBFRACTIONS ON LIPID
METABOLISM IN DIET INDUCED HYPERCHOLESTEROLEMIC HAMSTRES:
CORREALTION WITH PLASMA METABOLOMIC PROFILE
by
ANDREEA GEAMANU
December 2013
Advisor: Dr. Smiti Gupta
Major: Nutrition and Food Science
Degree: Doctor of Philosophy
Background: Plasma HDL cholesterol levels are inversely related to
cardiovascular disease, which is the leading cause of death worldwide. This study
investigated the preventative effect of an algae infusion, ProAlgaZyme (PAZ) and its
subfractions (F1, F2, F3, F4) on plasma HDL in a hamster model. Further, the study
aimed to identify the biologically active fraction of PAZ and to determine the therapeutic
efficacy of the fraction in diet induced hypercholesterolemic hamsters over time. Also,
the current study investigated the changes in plasma metabolomic profile produced due
to the interventions, and correlated the results with the lipoprotein profile of the
hamsters.
Methods: Eighty male golden Syrian hamsters (8 weeks old) were randomized
into controls (CW and CP) or high fat diet (HW, HP, HF1, HF2, HF3, and HF4). During
the preventative intervention, an infusion of either 5% (HF1, HF2, HF3) or 20% (HP,
HF4) concentration (v/v) was administered via the drinking water for 4 weeks, while the
hamsters were being fed a high-fat diet (30% of calories from fat). Plasma lipids were
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assayed and liver samples subjected to reverse transcription polymerase chain reaction
(RT-PCR) to determine the relative transcription levels of genes involved in
HDL/reverse cholesterol transport metabolism, ie, ApoA1, ABCA1, CETP, and SRB1.
Lipid profile was correlated with plasma metabolomic profile using 1D

1

H NMR

spectroscopy and the biologically active fraction has been identified.
Further, the study aimed to determine the therapeutic effect of the active fraction
of PAZ. For this, 40 male Golden Syrian hamsters were fed a high fat diet for 4 weeks
prior to randomization into 5 groups, based on the number of days they received the
treatment. Thus animals in T3, T7, T10, T14, and T21 groups received the active
fraction for 3, 7, 10, 14, and 21 days, respectively, as their drinking fluid. HW group from
previous study was considered as control (T0, high fat diet and the active fraction for 0
days) for this study. Plasma lipid profile was assayed enzymatically, while RT-PCR
provided the alternative transcription levels of Apolipoprotein (Apo) A1 gene. Plasma
metabolomic profile was determined using 1H nuclear magnetic resonance (NMR)
spectroscopy and results correlated with the lipid profile of the hamsters.
Results: Non-HDL cholesterol was significantly reduced in the HP (P < 0.05),
HF3 and HF4 (P < 0.001) groups as compared with the HW group, while HDL
cholesterol showed a significant increase in the HP, HF3, and HF4 groups (P < 0.001).
Moreover, the total cholesterol/HDL ratio was significantly improved in the HP, HF1, and
HF2 (P < 0.05), and HF3 and HF4 (P < 0.001) groups. Real-time quantitative
polymerase chain reaction showed a significant increase in hepatic ApoA1 (HP, HF4)
and ABCA1 (HF3, HF4) expression, consistent with an increase in HDL production,
biogenesis, and maturation. A two-fold increase in SRB1 expression indicates that HF4
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further augments the reverse cholesterol transport mechanism. Reduction of CETP
expression (HF4) is consistent with a decrease in the transfer of cholesteryl ester to
LDL, further increasing the amount of cholesterol held as HDL particles. NMR
metabolomics approach showed a significant decrease in the concentration of several
small molecular weight molecules, including branched chain amino acids and
phosphocholine-containing molecules, in groups HP and HF4, when compared with HW
group. Since, F4 exhibited the most influence on plasma lipid and metabolomic profile, it
was further tested for its therapeutic effect.
Plasma HDL was significantly increased in T3 (P < 0.05) and T21 (P < 0.001),
while non-HDL cholesterol was significantly reduced in T3, T7, T10 (P < 0.001) and
T14, T21 (P < 0.01). Moreover, the total cholesterol/HDL was significantly lower in all
groups (P < 0.001) as compared with T0. Quantitative RT-PCR showed an increase in
Apo A1 expression in T10 (3x) and T21 (6x) groups. NMR data followed by multivariate
analysis showed a clear separation between T0 and T21 groups, indicating a difference
in their metabolomic profiles. Plasma concentrations of choline, phosphocholine,
glycerol-phosphocholine, betaine and carnitine metabolites were significantly lowered in
T21 group. These metabolites are associated with a reduced risk for atherosclerosis
and cardiovascular disease.
Conclusion: ProAlgaZyme and its subfractions significantly improved the
plasma cholesterol profile by lowering non-HDL and increasing HDL, possibly via the
reverse cholesterol transport mechanism. Also, the concentration of several proatherogenic small molecular weight metabolites has been decreased, indicating that
PAZ and F4 can be used as a preventative agent for hypercholesterolemia and
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atherosclerosis. Moreover, treatment with F4 also significantly improved plasma lipid
profile by increasing HDL and lowering non-HDL cholesterol, and reducing key risk
factor metabolites for atherosclerosis and cardiovascular disease.
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